



Clinical trial results:

An Open-Label, Phase Ia/Ib/Ila Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Summary

EudraCT number	2014-004852-77
Trial protocol	ES NL
Global end of trial date	13 March 2020

Results information

Result version number	v1 (current)
This version publication date	11 March 2021
First version publication date	11 March 2021

Trial information

Trial identification

Sponsor protocol code	GO29642
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01823835
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	19 November 2020
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	13 March 2020
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The primary objectives of this study were to assess the safety, tolerability and anti-tumor activity of GDC-0810 in women with locally advanced or metastatic ER+ (HER2-) breast cancer.

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 April 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 141
Country: Number of subjects enrolled	Netherlands: 2
Country: Number of subjects enrolled	Korea, Republic of: 3
Country: Number of subjects enrolled	Spain: 6
Worldwide total number of subjects	152
EEA total number of subjects	8

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	90
From 65 to 84 years	62
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

152 participants were enrolled into Phase I/IIa/Ib of the study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Phase Ia – Cohort 1

Arm description:

100 mg GDC-0810 once daily (QD) in fasting state.

Arm type	Experimental
Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg GDC-0810 once daily (QD) in fasting state.

Arm title	Phase Ia – Cohort 2
------------------	---------------------

Arm description:

200 mg GDC-0810 QD in fasting state.

Arm type	Experimental
Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

200 mg GDC-0810 QD in fasting state.

Arm title	Phase Ia – Cohort 3
------------------	---------------------

Arm description:

400 mg GDC-0810 QD in fasting state.

Arm type	Experimental
Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

400 mg GDC-0810 QD in fasting state.

Arm title	Phase Ia – Cohort 4
------------------	---------------------

Arm description: 600 mg GDC-0810 QD in fasting state.	
Arm type	Experimental
Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 600 mg GDC-0810 QD in fasting state.	
Arm title	Phase Ia – Cohort 5
Arm description: 600 mg GDC-0810 QD in non-fasting state.	
Arm type	Experimental
Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 600 mg GDC-0810 QD in non-fasting state.	
Arm title	Phase Ia – Cohort 6
Arm description: 300 mg GDC-0810 twice daily (BID) in fasting state.	
Arm type	Experimental
Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 300 mg GDC-0810 twice daily (BID) in fasting state.	
Arm title	Phase Ia – Cohort 7
Arm description: 800 mg GDC-0810 QD in fasting state.	
Arm type	Experimental
Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 800 mg GDC-0810 QD in fasting state.	
Arm title	Phase Ia – Cohort 8
Arm description: 800 mg GDC-0810 QD in non-fasting state.	
Arm type	Experimental

Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 800 mg GDC-0810 QD in non-fasting state.	
Arm title	Phase Ia – Cohort 9
Arm description: 400 mg GDC-0810 BID in fasting state.	
Arm type	Experimental
Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 400 mg GDC-0810 BID in fasting state.	
Arm title	Phase IIa – Cohort A1
Arm description: 600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had confirmed ER-a (ESR1) mutation of the ligand binding domain (LBD).	
Arm type	Experimental
Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 600 mg GDC-0810 QD.	
Arm title	Phase IIa – Cohort A2
Arm description: 600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and confirmed ER-a (ESR1) mutation of the LBD.	
Arm type	Experimental
Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 600 mg GDC-0810 QD.	
Arm title	Phase IIa – Cohort B1
Arm description: 600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had progressed following ≤ 1 prior therapy with an aromatase inhibitor (AI).	
Arm type	Experimental

Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 600 mg GDC-0810 QD.	
Arm title	Phase IIa – Cohort B2
Arm description: 600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and progressed following ≤ 1 prior therapy with an AI.	
Arm type	Experimental
Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 600 mg GDC-0810 QD.	
Arm title	Phase Ib – Cohort C1
Arm description: 400 mg GDC-0810 + 125 mg Palbociclib QD.	
Arm type	Experimental
Investigational medicinal product name	Palbociclib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details: 125 mg Palbociclib QD.	
Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 400 mg GDC-0810 QD.	
Arm title	Phase Ib – Cohort D1
Arm description: ≤ 600 mg GDC-0810 QD + LHRH agonist once monthly.	
Arm type	Experimental
Investigational medicinal product name	Luteinizing Hormone Releasing Hormone (LHRH) Agonist
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use
Dosage and administration details: LHRH agonist will be administered once monthly until disease progression, unacceptable toxicity, or withdrawal of consent	

Investigational medicinal product name	GDC-0810
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: ≤600 mg GDC-0810 QD.	

Number of subjects in period 1	Phase Ia – Cohort 1	Phase Ia – Cohort 2	Phase Ia – Cohort 3
Started	3	4	4
Completed	0	0	0
Not completed	3	4	4
Consent withdrawn by subject	-	-	1
Physician decision	-	-	-
Study Termination	-	-	-
Adverse event, non-fatal	-	-	-
Progressive Disease	3	4	3

Number of subjects in period 1	Phase Ia – Cohort 4	Phase Ia – Cohort 5	Phase Ia – Cohort 6
Started	6	6	6
Completed	0	0	0
Not completed	6	6	6
Consent withdrawn by subject	-	-	-
Physician decision	-	-	-
Study Termination	-	1	-
Adverse event, non-fatal	-	1	-
Progressive Disease	6	4	6

Number of subjects in period 1	Phase Ia – Cohort 7	Phase Ia – Cohort 8	Phase Ia – Cohort 9
Started	6	3	3
Completed	0	0	0
Not completed	6	3	3
Consent withdrawn by subject	-	-	-
Physician decision	-	-	-
Study Termination	-	-	-
Adverse event, non-fatal	1	-	-
Progressive Disease	5	3	3

Number of subjects in period 1	Phase IIa – Cohort A1	Phase IIa – Cohort A2	Phase IIa – Cohort B1
Started	19	10	53

Completed	0	0	0
Not completed	19	10	53
Consent withdrawn by subject	1	1	2
Physician decision	-	-	2
Study Termination	-	-	1
Adverse event, non-fatal	-	1	2
Progressive Disease	18	8	46

Number of subjects in period 1	Phase IIa – Cohort B2	Phase Ib – Cohort C1	Phase Ib – Cohort D1
Started	19	4	6
Completed	0	0	0
Not completed	19	4	6
Consent withdrawn by subject	1	-	-
Physician decision	-	-	-
Study Termination	-	-	-
Adverse event, non-fatal	-	-	-
Progressive Disease	18	4	6

Baseline characteristics

Reporting groups

Reporting group title	Phase Ia – Cohort 1
Reporting group description: 100 mg GDC-0810 once daily (QD) in fasting state.	
Reporting group title	Phase Ia – Cohort 2
Reporting group description: 200 mg GDC-0810 QD in fasting state.	
Reporting group title	Phase Ia – Cohort 3
Reporting group description: 400 mg GDC-0810 QD in fasting state.	
Reporting group title	Phase Ia – Cohort 4
Reporting group description: 600 mg GDC-0810 QD in fasting state.	
Reporting group title	Phase Ia – Cohort 5
Reporting group description: 600 mg GDC-0810 QD in non-fasting state.	
Reporting group title	Phase Ia – Cohort 6
Reporting group description: 300 mg GDC-0810 twice daily (BID) in fasting state.	
Reporting group title	Phase Ia – Cohort 7
Reporting group description: 800 mg GDC-0810 QD in fasting state.	
Reporting group title	Phase Ia – Cohort 8
Reporting group description: 800 mg GDC-0810 QD in non-fasting state.	
Reporting group title	Phase Ia – Cohort 9
Reporting group description: 400 mg GDC-0810 BID in fasting state.	
Reporting group title	Phase IIa – Cohort A1
Reporting group description: 600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had confirmed ER-a (ESR1) mutation of the ligand binding domain (LBD).	
Reporting group title	Phase IIa – Cohort A2
Reporting group description: 600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and confirmed ER-a (ESR1) mutation of the LBD.	
Reporting group title	Phase IIa – Cohort B1
Reporting group description: 600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had progressed following ≤ 1 prior therapy with an aromatase inhibitor (AI).	
Reporting group title	Phase IIa – Cohort B2
Reporting group description: 600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and progressed following ≤ 1 prior therapy with an AI.	
Reporting group title	Phase Ib – Cohort C1
Reporting group description: 400 mg GDC-0810 + 125 mg Palbociclib QD.	
Reporting group title	Phase Ib – Cohort D1
Reporting group description: ≤ 600 mg GDC-0810 QD + LHRH agonist once monthly.	

Reporting group values	Phase Ia – Cohort 1	Phase Ia – Cohort 2	Phase Ia – Cohort 3
Number of subjects	3	4	4
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	1	2	3
From 65-84 years	2	2	1
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	66.3	63.5	60.8
standard deviation	± 5.7	± 9.6	± 6.9
Sex: Female, Male Units:			
Female	3	4	4
Male	0	0	0
Race/Ethnicity, Customized Units: Subjects			
Asian	0	0	0
Black or African American	0	0	1
White	2	4	3
Other	1	0	0
Unknown	0	0	0

Reporting group values	Phase Ia – Cohort 4	Phase Ia – Cohort 5	Phase Ia – Cohort 6
Number of subjects	6	6	6
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	5	1	4
From 65-84 years	1	5	2
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	55.3	69.3	56.2
standard deviation	± 8.5	± 7.2	± 12.8

Sex: Female, Male			
Units:			
Female	6	6	6
Male	0	0	0
Race/Ethnicity, Customized			
Units: Subjects			
Asian	0	1	1
Black or African American	0	0	0
White	6	5	4
Other	0	0	0
Unknown	0	0	1

Reporting group values	Phase Ia – Cohort 7	Phase Ia – Cohort 8	Phase Ia – Cohort 9
Number of subjects	6	3	3
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	4	3	1
From 65-84 years	2	0	2
85 years and over	0	0	0
Age Continuous			
Units: Years			
arithmetic mean	50.5	58.3	64.7
standard deviation	± 14.6	± 3.5	± 4.0
Sex: Female, Male			
Units:			
Female	6	3	3
Male	0	0	0
Race/Ethnicity, Customized			
Units: Subjects			
Asian	0	0	0
Black or African American	0	0	0
White	6	3	3
Other	0	0	0
Unknown	0	0	0

Reporting group values	Phase IIa – Cohort A1	Phase IIa – Cohort A2	Phase IIa – Cohort B1
Number of subjects	19	10	53
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0

Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	15	4	28
From 65-84 years	4	6	25
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	55.4	63.4	61.9
standard deviation	± 12.2	± 8.9	± 9.3
Sex: Female, Male Units:			
Female	19	10	53
Male	0	0	0
Race/Ethnicity, Customized Units: Subjects			
Asian	2	1	2
Black or African American	0	0	0
White	17	8	46
Other	0	0	0
Unknown	0	1	5

Reporting group values	Phase IIa – Cohort B2	Phase Ib – Cohort C1	Phase Ib – Cohort D1
Number of subjects	19	4	6
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	10	3	6
From 65-84 years	9	1	0
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	62.6	58.5	41.7
standard deviation	± 12.2	± 13.1	± 8.9
Sex: Female, Male Units:			
Female	19	4	6
Male	0	0	0
Race/Ethnicity, Customized Units: Subjects			
Asian	0	0	3
Black or African American	2	0	0
White	15	4	1
Other	0	0	0

Unknown	2	0	2
---------	---	---	---

Reporting group values	Total		
Number of subjects	152		
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	90		
From 65-84 years	62		
85 years and over	0		
Age Continuous Units: Years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male Units:			
Female	152		
Male	0		
Race/Ethnicity, Customized Units: Subjects			
Asian	10		
Black or African American	3		
White	127		
Other	1		
Unknown	11		

End points

End points reporting groups

Reporting group title	Phase Ia – Cohort 1
Reporting group description: 100 mg GDC-0810 once daily (QD) in fasting state.	
Reporting group title	Phase Ia – Cohort 2
Reporting group description: 200 mg GDC-0810 QD in fasting state.	
Reporting group title	Phase Ia – Cohort 3
Reporting group description: 400 mg GDC-0810 QD in fasting state.	
Reporting group title	Phase Ia – Cohort 4
Reporting group description: 600 mg GDC-0810 QD in fasting state.	
Reporting group title	Phase Ia – Cohort 5
Reporting group description: 600 mg GDC-0810 QD in non-fasting state.	
Reporting group title	Phase Ia – Cohort 6
Reporting group description: 300 mg GDC-0810 twice daily (BID) in fasting state.	
Reporting group title	Phase Ia – Cohort 7
Reporting group description: 800 mg GDC-0810 QD in fasting state.	
Reporting group title	Phase Ia – Cohort 8
Reporting group description: 800 mg GDC-0810 QD in non-fasting state.	
Reporting group title	Phase Ia – Cohort 9
Reporting group description: 400 mg GDC-0810 BID in fasting state.	
Reporting group title	Phase IIa – Cohort A1
Reporting group description: 600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had confirmed ER-a (ESR1) mutation of the ligand binding domain (LBD).	
Reporting group title	Phase IIa – Cohort A2
Reporting group description: 600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and confirmed ER-a (ESR1) mutation of the LBD.	
Reporting group title	Phase IIa – Cohort B1
Reporting group description: 600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had progressed following ≤ 1 prior therapy with an aromatase inhibitor (AI).	
Reporting group title	Phase IIa – Cohort B2
Reporting group description: 600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and progressed following ≤ 1 prior therapy with an AI.	
Reporting group title	Phase Ib – Cohort C1
Reporting group description: 400 mg GDC-0810 + 125 mg Palbociclib QD.	
Reporting group title	Phase Ib – Cohort D1
Reporting group description: ≤ 600 mg GDC-0810 QD + LHRH agonist once monthly.	

Primary: Phase Ia: Maximum Tolerated Dose of GDC-0810 When Used as a Single Agent

End point title	Phase Ia: Maximum Tolerated Dose of GDC-0810 When Used as a Single Agent ^{[1][2]}
-----------------	--------------------------------------------------------------------------------------------

End point description:

Maximum Tolerated Dose (MTD) is determined based on the number of Dose Limiting Toxicities (DLTs) experienced by the participants. DLTs were defined as any of the following adverse events (AEs) that are deemed by the investigator or the Sponsor to be related to study drug (toxicities will be attributed to single agent GDC-0810 unless they are clearly related to disease progression or can clearly be attributed to a cause other than GDC-0810 administration):

- Any grade ≥ 3 non-hematologic toxicity (excluding alopecia)
- Any grade ≥ 3 hematologic toxicity of > 7 days' duration
- Any grade toxicity that leads to study drug interruption of > 7 days' duration

End point type	Primary
----------------	---------

End point timeframe:

Day -7 through the first cycle (28 days) of treatment (35 days total)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ia – Cohort 1	Phase Ia – Cohort 2	Phase Ia – Cohort 3	Phase Ia – Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[3]	0 ^[4]	0 ^[5]	0 ^[6]
Units: milligram (mg)				
number (not applicable)				

Notes:

[3] - The MTD could not be determined.

[4] - The MTD could not be determined.

[5] - The MTD could not be determined.

[6] - The MTD could not be determined.

End point values	Phase Ia – Cohort 5	Phase Ia – Cohort 6	Phase Ia – Cohort 7	Phase Ia – Cohort 8
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[7]	0 ^[8]	0 ^[9]	0 ^[10]
Units: milligram (mg)				
number (not applicable)				

Notes:

[7] - The MTD could not be determined.

[8] - The MTD could not be determined.

[9] - The MTD could not be determined.

[10] - The MTD could not be determined.

End point values	Phase Ia – Cohort 9			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[11]			
Units: milligram (mg)				

number (not applicable)				
-------------------------	--	--	--	--

Notes:

[11] - The MTD could not be determined.

Statistical analyses

No statistical analyses for this end point

Primary: Phase Ia: Recommended Phase II Dose (RP2D) of GDC-0810 When Used as a Single Agent

End point title	Phase Ia: Recommended Phase II Dose (RP2D) of GDC-0810 When Used as a Single Agent ^{[12][13]}
-----------------	--------------------------------------------------------------------------------------------------------

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Day -7 through the first cycle (28 days) of treatment (35 days total)

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ia – Cohort 1	Phase Ia – Cohort 2	Phase Ia – Cohort 3	Phase Ia – Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	4	6
Units: milligram (mg)				
number (not applicable)	600	600	600	600

End point values	Phase Ia – Cohort 5	Phase Ia – Cohort 6	Phase Ia – Cohort 7	Phase Ia – Cohort 8
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	3
Units: milligram (mg)				
number (not applicable)	600	600	600	600

End point values	Phase Ia – Cohort 9			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: milligram (mg)				
number (not applicable)	600			

Statistical analyses

No statistical analyses for this end point

Primary: Phase IIa: Percentage of Participants With Confirmed Objective Tumor Response of GDC-0810 According to RECIST v1.1

End point title	Phase IIa: Percentage of Participants With Confirmed Objective Tumor Response of GDC-0810 According to RECIST v1.1 ^{[14][15]}
-----------------	----------------------------------------------------------------------------------------------------------------------------------------

End point description:

Objective response (OR) is defined as a complete response (CR) or partial response (PR) as determined by investigator assessment according to RECIST v1.1. OR was based on criteria related to changes in size of target lesions. CR was the disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

End point type	Primary
----------------	---------

End point timeframe:

Screening and every 8 weeks from Cycle 1 Day 1 until Cycle 12, thereafter every 3 months until disease progression (up to 3 years)

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this endpoint.

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase IIa – Cohort A1	Phase IIa – Cohort A2	Phase IIa – Cohort B1	Phase IIa – Cohort B2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	19	10	53	19
Units: percentage of participants				
number (not applicable)				
Complete Response	0	0	0	0
Partial Response	0	0	7.5	0

Statistical analyses

No statistical analyses for this end point

Primary: Phase IIa: Percentage of Participants With Clinical Benefit Response of GDC-0810 According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

End point title	Phase IIa: Percentage of Participants With Clinical Benefit Response of GDC-0810 According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) ^{[16][17]}
-----------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Clinical Benefit Response (CBR) is defined as the percentage of participants achieving confirmed RECIST v1.1 defined CR, PR, and/or stable disease. CR was the disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Stable disease was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

End point type	Primary
----------------	---------

End point timeframe:

Screening and every 8 weeks from Cycle 1 Day 1 until Cycle 12, thereafter every 3 months until disease progression (up to 3 years)

Notes:

[16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase IIa – Cohort A1	Phase IIa – Cohort A2	Phase IIa – Cohort B1	Phase IIa – Cohort B2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	19	10	53	19
Units: percentage of participants				
number (not applicable)	5.3	10.0	28.3	15.8

Statistical analyses

No statistical analyses for this end point

Primary: Phase Ib: RP2D of GDC-0810 When Used in Combination With Palbociclib and/or LHRH

End point title	Phase Ib: RP2D of GDC-0810 When Used in Combination With Palbociclib and/or LHRH ^{[18][19]}
-----------------	------------------------------------------------------------------------------------------------------

End point description:

End point type	Primary
----------------	---------

End point timeframe:

first cycle (Days 1 to 28 of a 28-day schedule)

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ib – Cohort C1	Phase Ib – Cohort D1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[20]	0 ^[21]		
Units: mg				

Notes:

[20] - Data not available due to the discontinuation of GDC-0810 development.

[21] - Data not available due to the discontinuation of GDC-0810 development.

Statistical analyses

No statistical analyses for this end point

Secondary: All Phases: Percentage of Participants With Adverse Events (AEs)

End point title	All Phases: Percentage of Participants With Adverse Events (AEs)
-----------------	------------------------------------------------------------------

End point description:

End point type	Secondary
End point timeframe:	
up to 3 years	

End point values	Phase Ia – Cohort 1	Phase Ia – Cohort 2	Phase Ia – Cohort 3	Phase Ia – Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	4	6
Units: percentage of participants	100	100	100	100

End point values	Phase Ia – Cohort 5	Phase Ia – Cohort 6	Phase Ia – Cohort 7	Phase Ia – Cohort 8
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	3
Units: percentage of participants	100	100	100	100

End point values	Phase Ia – Cohort 9	Phase IIa – Cohort A1	Phase IIa – Cohort A2	Phase IIa – Cohort B1
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	19	10	53
Units: percentage of participants	100	100	100	100

End point values	Phase IIa – Cohort B2	Phase Ib – Cohort C1	Phase Ib – Cohort D1	
------------------	-----------------------	----------------------	----------------------	--

Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	19	4	6	
Units: percentage of participants	100	100	100	

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ia: Maximum Plasma Concentration (Cmax) of GDC-0810 Single Agent and Its Glucuronide Metabolites

End point title	Phase Ia: Maximum Plasma Concentration (Cmax) of GDC-0810 Single Agent and Its Glucuronide Metabolites ^[22]
-----------------	------------------------------------------------------------------------------------------------------------------------

End point description:

Maximum Plasma Concentration (Cmax) has been calculated following oral administration of single and multiple doses (at steady state) of GDC-0810. Here 99999 represents data that were not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Day -7 at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 (Day -6), and 48 (Day -5) hours postdose; Day 29 (Cycle 2 Day 1) at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose (Cycle 2 Day 2, prior to the next dose)

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ia – Cohort 1	Phase Ia – Cohort 2	Phase Ia – Cohort 3	Phase Ia – Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	4	6
Units: micrograms per milliliter (ug/mL)				
arithmetic mean (standard deviation)				
GDC-0810 (Single Dose)	2.29 (± 1.24)	3.76 (± 0.599)	9.4 (± 2.53)	12.7 (± 5.36)
GDC-0810 (Multiple Doses)	2.59 (± 1.43)	3.26 (± 1.11)	9.08 (± 3.43)	11.8 (± 6.61)
GDC-0810-N-Glucuronide (Single Dose)	0.0171 (± 0.021)	0.0535 (± 0.015)	0.177 (± 0.1)	0.468 (± 0.388)
GDC-0810-N-Glucuronide (Multiple Doses)	0.067 (± 0.055)	0.061 (± 0.0271)	0.184 (± 0.0832)	0.416 (± 0.346)
GDC-0810-Acyl-Glucuronide (Single Dose)	99999 (± 99999)	99999 (± 99999)	1.46 (± 0.997)	3 (± 0.827)
GDC-0810-Acyl-Glucuronide (Multiple Doses)	99999 (± 99999)	99999 (± 99999)	1.89 (± 1.34)	3.64 (± 2.96)

End point values	Phase Ia – Cohort 5	Phase Ia – Cohort 6	Phase Ia – Cohort 7	Phase Ia – Cohort 8
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	3
Units: micrograms per milliliter (ug/mL)				
arithmetic mean (standard deviation)				
GDC-0810 (Single Dose)	22.2 (± 11.6)	9.73 (± 4.5)	15.9 (± 3.13)	15.6 (± 4.97)

GDC-0810 (Multiple Doses)	25 (± 8.35)	8.89 (± 3.96)	18.4 (± 4.84)	25.5 (± 9.3)
GDC-0810-N-Glucuronide (Single Dose)	0.691 (± 0.526)	0.299 (± 0.171)	1.38 (± 1.19)	0.369 (± 0.338)
GDC-0810-N-Glucuronide (Multiple Doses)	0.723 (± 0.338)	0.181 (± 0.0846)	0.74 (± 0.327)	1.17 (± 0.893)
GDC-0810-Acyl-Glucuronide (Single Dose)	2.26 (± 1.24)	1.35 (± 0.876)	7.02 (± 8.19)	1.29 (± 0.617)
GDC-0810-Acyl-Glucuronide (Multiple Doses)	3.16 (± 1.2)	0.993 (± 0.435)	3.37 (± 2.34)	4.62 (± 2.19)

End point values	Phase Ia – Cohort 9			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: micrograms per milliliter (ug/mL)				
arithmetic mean (standard deviation)				
GDC-0810 (Single Dose)	10.1 (± 4.23)			
GDC-0810 (Multiple Doses)	13.9 (± 4.87)			
GDC-0810-N-Glucuronide (Single Dose)	0.153 (± 0.0421)			
GDC-0810-N-Glucuronide (Multiple Doses)	0.308 (± 0.148)			
GDC-0810-Acyl-Glucuronide (Single Dose)	1.36 (± 0.421)			
GDC-0810-Acyl-Glucuronide (Multiple Doses)	2.82 (± 1.43)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ia: Time to Maximum Concentration (Tmax) of GDC-0810 Single Agent and Its Glucuronide Metabolites

End point title	Phase Ia: Time to Maximum Concentration (Tmax) of GDC-0810 Single Agent and Its Glucuronide Metabolites ^[23]
-----------------	-------------------------------------------------------------------------------------------------------------------------

End point description:

Time to Maximum Concentration (Tmax) has been calculated following oral administration of single and multiple doses (at steady state) of GDC-0810. Here 99999 represents data that were not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Day -7 at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 (Day -6), and 48 (Day -5) hours postdose; Day 29 (Cycle 2 Day 1) at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose (Cycle 2 Day 2, prior to the next dose)

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ia – Cohort 1	Phase Ia – Cohort 2	Phase Ia – Cohort 3	Phase Ia – Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	4	6
Units: hour (hr)				
median (full range (min-max))				
GDC-0810 (Single Dose)	1.5 (1.5 to 2)	1.71 (1.45 to 2)	2 (1 to 3)	2.99 (1.25 to 4)
GDC-0810 (Multiple Doses)	1.47 (0.95 to 2)	0.9 (0.45 to 1)	1.55 (1.07 to 1.68)	2.48 (1.93 to 6.45)
GDC-0810-N-Glucuronide (Single Dose)	0.5 (0.5 to 1.5)	1.95 (1.5 to 2)	2 (1.52 to 3)	2.85 (2 to 4)
GDC-0810-N-Glucuronide (Multiple Doses)	2 (0 to 2.05)	1 (0.9 to 1.48)	1.64 (1.52 to 2.08)	3.49 (1.93 to 4.45)
GDC-0810-Acyl-Glucuronide (Single Dose)	99999 (99999 to 99999)	99999 (99999 to 99999)	2 (1.52 to 3)	2.85 (2.72 to 2.98)
GDC-0810-Acyl-Glucuronide (Multiple Doses)	99999 (99999 to 99999)	99999 (99999 to 99999)	1.84 (1.52 to 2.17)	3.53 (3.07 to 4)

End point values	Phase Ia – Cohort 5	Phase Ia – Cohort 6	Phase Ia – Cohort 7	Phase Ia – Cohort 8
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	3
Units: hour (hr)				
median (full range (min-max))				
GDC-0810 (Single Dose)	3.01 (1.5 to 6)	1.48 (0.217 to 3.03)	3.04 (2.17 to 4)	2 (2 to 4.07)
GDC-0810 (Multiple Doses)	2.95 (1.95 to 4.03)	1.65 (0.917 to 3.07)	1.59 (1.08 to 1.92)	2.93 (1.53 to 6.3)
GDC-0810-N-Glucuronide (Single Dose)	3.51 (1.5 to 6.07)	1.72 (0.217 to 3.03)	3.54 (3 to 4)	3 (2 to 4.07)
GDC-0810-N-Glucuronide (Multiple Doses)	2.95 (1.95 to 4.03)	1.65 (0.917 to 3.07)	2.27 (1.08 to 3.03)	2.93 (1.53 to 6.3)
GDC-0810-Acyl-Glucuronide (Single Dose)	3.51 (2 to 6.07)	1.98 (0.717 to 3.03)	3.54 (3 to 4)	3 (2 to 4.07)
GDC-0810-Acyl-Glucuronide (Multiple Doses)	2.95 (1.95 to 4.03)	1.65 (0.917 to 3.07)	2.27 (1.08 to 3.03)	2.93 (1.53 to 6.3)

End point values	Phase Ia – Cohort 9			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: hour (hr)				
median (full range (min-max))				
GDC-0810 (Single Dose)	1.88 (1 to 3)			
GDC-0810 (Multiple Doses)	2.05 (1.47 to 2.42)			
GDC-0810-N-Glucuronide (Single Dose)	1.88 (1 to 3)			
GDC-0810-N-Glucuronide (Multiple Doses)	2.05 (1.47 to 3.37)			
GDC-0810-Acyl-Glucuronide (Single Dose)	2.98 (1 to 3)			

GDC-0810-Acyl-Glucuronide (Multiple Doses)	2.05 (2 to 3.37)			
--------------------------------------------	------------------	--	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ia: Area Under the Concentration-time Curves at 6 hours (AUC0-6) of GDC-0810 Single Agent and Its Glucuronide Metabolites

End point title	Phase Ia: Area Under the Concentration-time Curves at 6 hours (AUC0-6) of GDC-0810 Single Agent and Its Glucuronide Metabolites ^[24]
-----------------	-------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Here 99999 represents data that were not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Day -7 at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 (Day -6), and 48 (Day -5) hours postdose; Day 29 (Cycle 2 Day 1) at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose (Cycle 2 Day 2, prior to the next dose)

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ia – Cohort 1	Phase Ia – Cohort 2	Phase Ia – Cohort 3	Phase Ia – Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	4	6
Units: hr*ug/mL				
arithmetic mean (standard deviation)				
GDC-0810 (Single Dose)	3.18 (± 1.65)	6.78 (± 1.19)	23.7 (± 11.3)	34.3 (± 14.4)
GDC-0810 (Multiple Doses)	4.83 (± 2.3)	6.19 (± 2.18)	18.8 (± 4.76)	41.1 (± 27.5)
GDC-0810-N-Glucuronide (Single Dose)	0.0401 (± 0.0197)	0.116 (± 0.0729)	0.321 (± 0.149)	1.16 (± 0.815)
GDC-0810-N-Glucuronide (Multiple Doses)	0.105 (± 0.0724)	0.103 (± 0.0335)	0.321 (± 0.105)	1.37 (± 1.21)
GDC-0810-Acyl-Glucuronide (Single Dose)	99999 (± 99999)	99999 (± 99999)	3.18 (± 1.77)	8.25 (± 4.54)
GDC-0810-Acyl-Glucuronide (Multiple Doses)	99999 (± 99999)	99999 (± 99999)	3.72 (± 1.91)	13 (± 11.1)

End point values	Phase Ia – Cohort 5	Phase Ia – Cohort 6	Phase Ia – Cohort 7	Phase Ia – Cohort 8
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	3
Units: hr*ug/mL				
arithmetic mean (standard deviation)				
GDC-0810 (Single Dose)	58.2 (± 28.9)	18.8 (± 7.38)	51.1 (± 18)	48.3 (± 28.4)

GDC-0810 (Multiple Doses)	74.9 (± 30.1)	19.3 (± 7.01)	65.7 (± 20.6)	70.5 (± 22)
GDC-0810-N-Glucuronide (Single Dose)	1.36 (± 0.917)	0.486 (± 0.36)	3.81 (± 4.15)	0.938 (± 0.983)
GDC-0810-N-Glucuronide (Multiple Doses)	1.83 (± 1.01)	0.409 (± 0.23)	2.63 (± 1.01)	2.08 (± 1.15)
GDC-0810-Acyl-Glucuronide (Single Dose)	5.29 (± 2.71)	2.76 (± 2.23)	21.1 (± 26.9)	3.99 (± 2.29)
GDC-0810-Acyl-Glucuronide (Multiple Doses)	8.25 (± 3.47)	2.03 (± 0.669)	14 (± 11.1)	10.2 (± 3.61)

End point values	Phase Ia – Cohort 9			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: hr*ug/mL				
arithmetic mean (standard deviation)				
GDC-0810 (Single Dose)	22.1 (± 5.43)			
GDC-0810 (Multiple Doses)	43 (± 26)			
GDC-0810-N-Glucuronide (Single Dose)	0.29 (± 0.0295)			
GDC-0810-N-Glucuronide (Multiple Doses)	0.974 (± 0.605)			
GDC-0810-Acyl-Glucuronide (Single Dose)	3.27 (± 1.03)			
GDC-0810-Acyl-Glucuronide (Multiple Doses)	8.45 (± 5.79)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ia: Area Under the Concentration-time Curves at 24 hours (AUC0-24) of GDC-0810 Single Agent and Its Glucuronide Metabolites

End point title	Phase Ia: Area Under the Concentration-time Curves at 24 hours (AUC0-24) of GDC-0810 Single Agent and Its Glucuronide Metabolites ^[25]
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Here 99999 represents data that were not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Day -7 at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 (Day -6), and 48 (Day -5) hours postdose; Day 29 (Cycle 2 Day 1) at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose (Cycle 2 Day 2, prior to the next dose)

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ia – Cohort 1	Phase Ia – Cohort 2	Phase Ia – Cohort 3	Phase Ia – Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	4	6
Units: hr*ug/mL				
arithmetic mean (standard deviation)				
GDC-0810 (Single Dose)	3.58 (± 1.75)	8.81 (± 2.52)	28.5 (± 15.6)	44.7 (± 19.5)
GDC-0810 (Multiple Doses)	5.34 (± 2.99)	7.36 (± 1.32)	22.8 (± 6.14)	66.9 (± 46.8)
GDC-0810-N-Glucuronide (Single Dose)	0.13 (± 0.0197)	0.224 (± 0.109)	0.413 (± 0.152)	1.54 (± 1.08)
GDC-0810-N-Glucuronide (Multiple Doses)	0.13 (± 0.0141)	0.132 (± 0.0253)	0.413 (± 0.121)	2.63 (± 2.21)
GDC-0810-Acyl-Glucuronide (Single Dose)	99999 (± 99999)	99999 (± 99999)	3.76 (± 2.13)	11.4 (± 7.43)
GDC-0810-Acyl-Glucuronide (Multiple Doses)	99999 (± 99999)	99999 (± 99999)	4.42 (± 2.27)	21.8 (± 21.2)

End point values	Phase Ia – Cohort 5	Phase Ia – Cohort 6	Phase Ia – Cohort 7	Phase Ia – Cohort 8
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	3
Units: hr*ug/mL				
arithmetic mean (standard deviation)				
GDC-0810 (Single Dose)	101 (± 49.9)	41.2 (± 15.9)	61.8 (± 25.5)	95.1 (± 76.4)
GDC-0810 (Multiple Doses)	102 (± 35.9)	44.2 (± 14.5)	80.4 (± 26.8)	75.2 (± 15.4)
GDC-0810-N-Glucuronide (Single Dose)	2.08 (± 1.02)	1.07 (± 0.786)	5.67 (± 7.17)	1.83 (± 2.04)
GDC-0810-N-Glucuronide (Multiple Doses)	2.64 (± 1.4)	1.09 (± 0.594)	3.72 (± 1.81)	2.35 (± 1.57)
GDC-0810-Acyl-Glucuronide (Single Dose)	8.59 (± 3.82)	6.03 (± 4.89)	30.6 (± 44)	7.64 (± 5.51)
GDC-0810-Acyl-Glucuronide (Multiple Doses)	10.4 (± 4.07)	4.61 (± 1.34)	18.1 (± 16.3)	12 (± 5.44)

End point values	Phase Ia – Cohort 9			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: hr*ug/mL				
arithmetic mean (standard deviation)				
GDC-0810 (Single Dose)	47.7 (± 11.4)			
GDC-0810 (Multiple Doses)	109 (± 73.3)			
GDC-0810-N-Glucuronide (Single Dose)	0.649 (± 0.055)			
GDC-0810-N-Glucuronide (Multiple Doses)	2.66 (± 1.58)			
GDC-0810-Acyl-Glucuronide (Single Dose)	7.1 (± 1.96)			
GDC-0810-Acyl-Glucuronide (Multiple Doses)	20.8 (± 14.9)			

Statistical analyses

No statistical analyses for this end point

Secondary: Area under the concentration–time curve from Time 0 to infinity (AUC0-Inf)

End point title	Area under the concentration–time curve from Time 0 to infinity (AUC0-Inf) ^[26]
-----------------	--------------------------------------------------------------------------------------------

End point description:

Here 999999 represents data that were not estimable.

End point type	Secondary
----------------	-----------

End point timeframe:

Day -7 at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 (Day -6), and 48 (Day -5) hours postdose; Day 29 (Cycle 2 Day 1) at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose (Cycle 2 Day 2, prior to the next dose)

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ia – Cohort 1	Phase Ia – Cohort 2	Phase Ia – Cohort 3	Phase Ia – Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	4	5
Units: hr*ug/ml				
arithmetic mean (standard deviation)	5.3 (± 1.96)	10 (± 2.8)	30.8 (± 16.3)	40.5 (± 11.3)

End point values	Phase Ia – Cohort 5	Phase Ia – Cohort 6	Phase Ia – Cohort 7	Phase Ia – Cohort 8
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	4	3
Units: hr*ug/ml				
arithmetic mean (standard deviation)	114 (± 57.4)	999999 (± 999999)	65.7 (± 28)	101 (± 78.5)

End point values	Phase Ia – Cohort 9			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: hr*ug/ml				
arithmetic mean (standard deviation)	999999 (± 999999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ia: Plasma Half-life (t1/2) of GDC-0810 Single Agent

End point title	Phase Ia: Plasma Half-life (t1/2) of GDC-0810 Single Agent ^[27]
-----------------	----------------------------------------------------------------------------

End point description:

Half-life (t1/2) was calculated after single dose administration and not at steady state. Here 999999 represents data that were not estimable.

End point type	Secondary
----------------	-----------

End point timeframe:

Day -7 at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 (Day -6), and 48 (Day -5) hours postdose; Day 29 (Cycle 2 Day 1) at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose (Cycle 2 Day 2, prior to the next dose)

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ia – Cohort 1	Phase Ia – Cohort 2	Phase Ia – Cohort 3	Phase Ia – Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	4	5
Units: hr				
arithmetic mean (standard deviation)	40.7 (± 3.47)	15.2 (± 2.35)	24.1 (± 17.3)	9.58 (± 3.41)

End point values	Phase Ia – Cohort 5	Phase Ia – Cohort 6	Phase Ia – Cohort 7	Phase Ia – Cohort 8
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	4	3
Units: hr				
arithmetic mean (standard deviation)	7.91 (± 2.67)	999999 (± 999999)	10.1 (± 1.59)	7.09 (± 3.23)

End point values	Phase Ia – Cohort 9			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: hr				
arithmetic mean (standard deviation)	999999 (± 999999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ia: Apparent Clearance (Cl/F)

End point title	Phase Ia: Apparent Clearance (Cl/F) ^[28]
-----------------	-----------------------------------------------------

End point description:

Here 999999 represents data that were not estimable.

End point type	Secondary
----------------	-----------

End point timeframe:

Day -7 at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 (Day -6), and 48 (Day -5) hours postdose; Day 29 (Cycle 2 Day 1) at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose (Cycle 2 Day 2, prior to the next dose)

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ia – Cohort 1	Phase Ia – Cohort 2	Phase Ia – Cohort 3	Phase Ia – Cohort 4
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	4	5
Units: L/hr				
arithmetic mean (standard deviation)	20.4 (± 6.43)	21 (± 4.94)	15.1 (± 5.56)	15.7 (± 4.13)

End point values	Phase Ia – Cohort 5	Phase Ia – Cohort 6	Phase Ia – Cohort 7	Phase Ia – Cohort 8
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	4	3
Units: L/hr				
arithmetic mean (standard deviation)	8.21 (± 8.38)	999999 (± 999999)	15.1 (± 9.45)	11.1 (± 6.23)

End point values	Phase Ia – Cohort 9			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: L/hr				
arithmetic mean (standard deviation)	999999 (± 999999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase IIa: Effect of GDC-0810 Single Agent on Ventricular Repolarization as Measured by Corrected QT Intervals (QTc) Using Fridericia's Formula

End point title	Phase IIa: Effect of GDC-0810 Single Agent on Ventricular Repolarization as Measured by Corrected QT Intervals (QTc) Using Fridericia's Formula ^[29]
-----------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Screening; on Cycle 2 Day 1 predose and at 1, 2, 3, 4, and 6 hours postdose; Cycle 3 Day 1 predose, and at 1, 3, and 6 hours post dose

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase IIa – Cohort A1	Phase IIa – Cohort A2	Phase IIa – Cohort B1	Phase IIa – Cohort B2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	19	10	53	19
Units: percentage of participants				
number (not applicable)				
≤ 450 milliseconds (msec)	100	66.7	91.2	100
>450 and ≤480 msec	0	33.3	8.8	0
Increase from baseline ≤30 msec	100	100	93.9	100
Increase from baseline >30 and ≤60 msec	0	0	6.1	0

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ib: Cmax of GDC-0810 in Combination With Palbociclib and/or an LHRH Agonist

End point title	Phase Ib: Cmax of GDC-0810 in Combination With Palbociclib and/or an LHRH Agonist ^[30]
-----------------	---------------------------------------------------------------------------------------------------

End point description:

Here 999999 represents data that were not estimable.

End point type	Secondary
----------------	-----------

End point timeframe:

Predose and at 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (Cohorts C1 and D1), Cycle 1 Day 8 (Cohort C1), and Cycle 2 Day 1 (Cohort D1)

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ib – Cohort C1	Phase Ib – Cohort D1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[31]	0 ^[32]		
Units: ug/ml				
arithmetic mean (standard deviation)	()	()		

Notes:

[31] - Data not available due to the discontinuation of GDC-0810 development.

[32] - Data not available due to the discontinuation of GDC-0810 development.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ib: Tmax of GDC-0810 in Combination With Palbociclib and/or an LHRH Agonist

End point title	Phase Ib: Tmax of GDC-0810 in Combination With Palbociclib and/or an LHRH Agonist ^[33]
-----------------	---------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Predose and at 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (Cohorts C1 and D1), Cycle 1 Day 8 (Cohort C1), and Cycle 2 Day 1 (Cohort D1)

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ib – Cohort C1	Phase Ib – Cohort D1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[34]	0 ^[35]		
Units: hr				
median (full range (min-max))	(to)	(to)		

Notes:

[34] - Data not available due to the discontinuation of GDC-0810 development.

[35] - Data not available due to the discontinuation of GDC-0810 development.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ib: AUC of GDC-0810 in Combination With Palbociclib and/or an

LHRH Agonist

End point title	Phase Ib: AUC of GDC-0810 in Combination With Palbociclib and/or an LHRH Agonist ^[36]
-----------------	--------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Predose and at 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (Cohorts C1 and D1), Cycle 1 Day 8 (Cohort C1), and Cycle 2 Day 1 (Cohort D1)

Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ib – Cohort C1	Phase Ib – Cohort D1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[37]	0 ^[38]		
Units: hr*ug/ml				
arithmetic mean (standard deviation)	()	()		

Notes:

[37] - Data not available due to the discontinuation of GDC-0810 development.

[38] - Data not available due to the discontinuation of GDC-0810 development.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ib: t/2 of GDC-0810 in Combination With Palbociclib and/or an LHRH Agonist

End point title	Phase Ib: t/2 of GDC-0810 in Combination With Palbociclib and/or an LHRH Agonist ^[39]
-----------------	--------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Predose and at 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (Cohorts C1 and D1), Cycle 1 Day 8 (Cohort C1), and Cycle 2 Day 1 (Cohort D1)

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ib – Cohort C1	Phase Ib – Cohort D1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[40]	0 ^[41]		
Units: hr				
arithmetic mean (standard deviation)	()	()		

Notes:

[40] - Data not available due to the discontinuation of GDC-0810 development.

[41] - Data not available due to the discontinuation of GDC-0810 development.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ib: Cmax of Palbociclib in Combination With GDC-0810 and/or an LHRH Agonist

End point title	Phase Ib: Cmax of Palbociclib in Combination With GDC-0810 and/or an LHRH Agonist ^[42]
-----------------	---------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort C1: Predose and at 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 and Cycle 1 Day 8

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ib – Cohort C1	Phase Ib – Cohort D1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[43]	0 ^[44]		
Units: ug/ml				
arithmetic mean (standard deviation)	()	()		

Notes:

[43] - Data not available due to the discontinuation of GDC-0810 development.

[44] - Data not available due to the discontinuation of GDC-0810 development.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ib: Tmax of Palbociclib in Combination With GDC-0810 and/or an LHRH Agonist

End point title	Phase Ib: Tmax of Palbociclib in Combination With GDC-0810 and/or an LHRH Agonist ^[45]
-----------------	---------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort C1: Predose and at 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 and Cycle 1 Day 8

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ib – Cohort C1	Phase Ib – Cohort D1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[46]	0 ^[47]		
Units: hr				
median (full range (min-max))	(to)	(to)		

Notes:

[46] - Data not available due to the discontinuation of GDC-0810 development.

[47] - Data not available due to the discontinuation of GDC-0810 development.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ib: AUC of Palbociclib in Combination With GDC-0810 and/or an LHRH Agonist

End point title	Phase Ib: AUC of Palbociclib in Combination With GDC-0810 and/or an LHRH Agonist ^[48]
-----------------	--------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort C1: Predose and at 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 and Cycle 1 Day 8

Notes:

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ib – Cohort C1	Phase Ib – Cohort D1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[49]	0 ^[50]		
Units: hr*ug/ml				
arithmetic mean (standard deviation)	()	()		

Notes:

[49] - Data not available due to the discontinuation of GDC-0810 development.

[50] - Data not available due to the discontinuation of GDC-0810 development.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ib: t/2 of Palbociclib in Combination With GDC-0810 and/or an LHRH Agonist

End point title	Phase Ib: t/2 of Palbociclib in Combination With GDC-0810 and/or an LHRH Agonist ^[51]
-----------------	--------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort C1: Predose and at 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 and Cycle 1 Day 8

Notes:

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ib – Cohort C1	Phase Ib – Cohort D1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[52]	0 ^[53]		
Units: hr				
arithmetic mean (standard deviation)	()	()		

Notes:

[52] - Data not available due to the discontinuation of GDC-0810 development.

[53] - Data not available due to the discontinuation of GDC-0810 development.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ib: Cmax of LHRH Agonist in Combination With GDC-0810 and/or Palbociclib

End point title	Phase Ib: Cmax of LHRH Agonist in Combination With GDC-0810 and/or Palbociclib ^[54]
-----------------	------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort D1: Predose and at 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 and Cycle 2 Day 1

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ib – Cohort C1	Phase Ib – Cohort D1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[55]	0 ^[56]		
Units: ug/ml				
arithmetic mean (standard deviation)	()	()		

Notes:

[55] - Data not available due to the discontinuation of GDC-0810 development.

[56] - Data not available due to the discontinuation of GDC-0810 development.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ib: Tmax of LHRH Agonist in Combination With GDC-0810 and/or Palbociclib

End point title	Phase Ib: Tmax of LHRH Agonist in Combination With GDC-0810 and/or Palbociclib ^[57]
-----------------	------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort D1: Predose and at 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 and Cycle 2 Day 1

Notes:

[57] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ib – Cohort C1	Phase Ib – Cohort D1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[58]	0 ^[59]		
Units: hr				
arithmetic mean (standard deviation)	()	()		

Notes:

[58] - Data not available due to the discontinuation of GDC-0810 development.

[59] - Data not available due to the discontinuation of GDC-0810 development.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ib: AUC of LHRH Agonist in Combination With GDC-0810 and/or an Palbociclib

End point title	Phase Ib: AUC of LHRH Agonist in Combination With GDC-0810 and/or an Palbociclib ^[60]
-----------------	--------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort D1: Predose and at 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 and Cycle 2 Day 1

Notes:

[60] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ib – Cohort C1	Phase Ib – Cohort D1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[61]	0 ^[62]		
Units: hr*ug/ml				
arithmetic mean (standard deviation)	()	()		

Notes:

[61] - Data not available due to the discontinuation of GDC-0810 development.

[62] - Data not available due to the discontinuation of GDC-0810 development.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase Ib: t/2 of LHRH Agonist in Combination With GDC-0810 and/or Palbociclib

End point title	Phase Ib: t/2 of LHRH Agonist in Combination With GDC-0810 and/or Palbociclib ^[63]
-----------------	-----------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort D1: Predose and at 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 and Cycle 2 Day 1

Notes:

[63] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was specific to participants in the relevant arm of the specific phase of the study.

End point values	Phase Ib – Cohort C1	Phase Ib – Cohort D1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[64]	0 ^[65]		
Units: hr				
arithmetic mean (standard deviation)	()	()		

Notes:

[64] - Data not available due to the discontinuation of GDC-0810 development.

[65] - Data not available due to the discontinuation of GDC-0810 development.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

up to 3 years

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

Reporting groups

Reporting group title	Phase Ia – Cohort 1
-----------------------	---------------------

Reporting group description:

100 mg GDC-0810 once daily (QD) in fasting state.

Reporting group title	Phase Ia - Cohort 2
-----------------------	---------------------

Reporting group description:

200 mg GDC-0810 QD in fasting state

Reporting group title	Phase Ia – Cohort 6
-----------------------	---------------------

Reporting group description:

300 mg GDC-0810 twice daily (BID) in fasting state.

Reporting group title	Phase Ia – Cohort 3
-----------------------	---------------------

Reporting group description:

400 mg GDC-0810 QD in fasting state.

Reporting group title	Phase Ia – Cohort 9
-----------------------	---------------------

Reporting group description:

400 mg GDC-0810 BID in fasting state.

Reporting group title	Phase Ia – Cohort 5
-----------------------	---------------------

Reporting group description:

600 mg GDC-0810 QD in non-fasting state.

Reporting group title	Phase Ia – Cohort 4
-----------------------	---------------------

Reporting group description:

600 mg GDC-0810 QD in fasting state.

Reporting group title	Phase Ia – Cohort 8
-----------------------	---------------------

Reporting group description:

800 mg GDC-0810 QD in non-fasting state.

Reporting group title	Phase Ia – Cohort 7
-----------------------	---------------------

Reporting group description:

800 mg GDC-0810 QD in fasting state.

Reporting group title	Phase IIa – Cohort A1
-----------------------	-----------------------

Reporting group description:

600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had confirmed ER-a (ESR1) mutation of the ligand binding domain (LBD).

Reporting group title	Phase IIa – Cohort A2
-----------------------	-----------------------

Reporting group description:

600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and confirmed ER-a (ESR1) mutation of the LBD.

Reporting group title	Phase IIa – Cohort B2
-----------------------	-----------------------

Reporting group description:

600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and progressed following ≤ 1 prior therapy with an AI.

Reporting group title	Phase IIa – Cohort B1
-----------------------	-----------------------

Reporting group description:

600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had progressed following ≤1 prior therapy with an aromatase inhibitor (AI).

Reporting group title	Phase Ib – Cohort D1
-----------------------	----------------------

Reporting group description:

≤600 mg GDC-0810 QD + LHRH agonist once monthly.

Reporting group title	Phase Ib – Cohort C1
-----------------------	----------------------

Reporting group description:

400 mg GDC-0810 + 125 mg Palbociclib QD.

Serious adverse events	Phase Ia – Cohort 1	Phase Ia – Cohort 2	Phase Ia – Cohort 6
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	4 / 6 (66.67%)
number of deaths (all causes)	1	1	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BREAST CANCER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TUMOUR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
DEEP VEIN THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTENSION			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VENOUS THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
DISEASE PROGRESSION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FATIGUE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
ENDOMETRIAL HYPERPLASIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
DYSпноEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			
alternative assessment type:			

Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY EMBOLISM			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMOTHORAX			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
DEVICE DISLOCATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
BLOOD BILIRUBIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
FALL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FRACTURE			
alternative assessment type:			

Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HIP FRACTURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ATRIAL FIBRILLATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC ARREST			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC FAILURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
HEADACHE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEIZURE			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SYNCOPE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
ANAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THROMBOCYTOPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
DIARRHOEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABDOMINAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASCITES			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NAUSEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VOMITING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
HEPATIC HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYDRONEPHROSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
ADRENAL INSUFFICIENCY			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
PAIN IN EXTREMITY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
APPENDICITIS PERFORATED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SKIN INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
HYPONATRAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase Ia – Cohort 3	Phase Ia – Cohort 9	Phase Ia – Cohort 5
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	3 / 6 (50.00%)
number of deaths (all causes)	0	0	2
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BREAST CANCER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TUMOUR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
DEEP VEIN THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTENSION			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VENOUS THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
DISEASE PROGRESSION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
FATIGUE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
ENDOMETRIAL HYPERPLASIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
DYSпноEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			
alternative assessment type:			

Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY EMBOLISM			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMOTHORAX			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
DEVICE DISLOCATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
BLOOD BILIRUBIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
FALL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FRACTURE			
alternative assessment type:			

Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HIP FRACTURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ATRIAL FIBRILLATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC ARREST			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC FAILURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Nervous system disorders			
HEADACHE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEIZURE			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SYNCOPE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
ANAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THROMBOCYTOPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
DIARRHOEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABDOMINAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASCITES			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NAUSEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VOMITING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
HEPATIC HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYDRONEPHROSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
ADRENAL INSUFFICIENCY			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
PAIN IN EXTREMITY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
APPENDICITIS PERFORATED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SKIN INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
HYPONATRAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase Ia – Cohort 4	Phase Ia – Cohort 8	Phase Ia – Cohort 7
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 6 (16.67%)	1 / 3 (33.33%)	1 / 6 (16.67%)
number of deaths (all causes)	1	0	1
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BREAST CANCER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TUMOUR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
DEEP VEIN THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTENSION			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VENOUS THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
DISEASE PROGRESSION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FATIGUE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
ENDOMETRIAL HYPERPLASIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
DYSпноEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			
alternative assessment type:			

Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY EMBOLISM			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMOTHORAX			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
DEVICE DISLOCATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
BLOOD BILIRUBIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Injury, poisoning and procedural complications			
FALL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FRACTURE			
alternative assessment type:			

Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HIP FRACTURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ATRIAL FIBRILLATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC ARREST			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC FAILURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
HEADACHE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEIZURE			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SYNCOPE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
ANAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THROMBOCYTOPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
DIARRHOEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABDOMINAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASCITES			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NAUSEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VOMITING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
HEPATIC HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYDRONEPHROSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
ADRENAL INSUFFICIENCY			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
PAIN IN EXTREMITY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
APPENDICITIS PERFORATED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SKIN INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
HYPONATRAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase IIa – Cohort A1	Phase IIa – Cohort A2	Phase IIa – Cohort B2
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 19 (21.05%)	1 / 10 (10.00%)	1 / 19 (5.26%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BREAST CANCER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TUMOUR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
DEEP VEIN THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTENSION			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VENOUS THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
DISEASE PROGRESSION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FATIGUE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
ENDOMETRIAL HYPERPLASIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
DYSпноEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			
alternative assessment type:			

Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY EMBOLISM			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMOTHORAX			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
DEVICE DISLOCATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
BLOOD BILIRUBIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
FALL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FRACTURE			
alternative assessment type:			

Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HIP FRACTURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ATRIAL FIBRILLATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC ARREST			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC FAILURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
HEADACHE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEIZURE			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SYNCOPE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
ANAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THROMBOCYTOPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
DIARRHOEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABDOMINAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASCITES			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NAUSEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VOMITING			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 19 (10.53%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
HEPATIC HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYDRONEPHROSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
ADRENAL INSUFFICIENCY			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
PAIN IN EXTREMITY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
APPENDICITIS PERFORATED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SKIN INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
HYPONATRAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase IIa – Cohort B1	Phase Ib – Cohort D1	Phase Ib – Cohort C1
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 53 (20.75%)	2 / 6 (33.33%)	1 / 4 (25.00%)
number of deaths (all causes)	3	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BREAST CANCER			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 53 (3.77%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
TUMOUR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
DEEP VEIN THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTENSION			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VENOUS THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
DISEASE PROGRESSION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FATIGUE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
ENDOMETRIAL HYPERPLASIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
DYSпноEA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			
alternative assessment type:			

Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY EMBOLISM			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMOTHORAX			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
DEVICE DISLOCATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
BLOOD BILIRUBIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
FALL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FRACTURE			
alternative assessment type:			

Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HIP FRACTURE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ATRIAL FIBRILLATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC ARREST			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC FAILURE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
HEADACHE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEIZURE			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SYNCOPE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
ANAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THROMBOCYTOPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
DIARRHOEA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABDOMINAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASCITES			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NAUSEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VOMITING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
HEPATIC HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
HYDRONEPHROSIS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
ADRENAL INSUFFICIENCY			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
PAIN IN EXTREMITY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
APPENDICITIS PERFORATED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPSIS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 53 (3.77%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SKIN INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
HYPONATRAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Phase Ia – Cohort 1	Phase Ia - Cohort 2	Phase Ia – Cohort 6
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	4 / 4 (100.00%)	6 / 6 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
METASTASIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SQUAMOUS CELL CARCINOMA OF SKIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Vascular disorders			
DEEP VEIN THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FLUSHING			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HAEMATOMA			

alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HOT FLUSH			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	3 / 6 (50.00%)
occurrences (all)	1	1	6
HYPERTENSION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
PALLOR			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LYMPHOEDEMA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
ASTHENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CHEST DISCOMFORT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CHEST PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CHILLS			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
FATIGUE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	2 / 6 (33.33%)
occurrences (all)	2	2	2
GAIT DISTURBANCE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
IMPAIRED HEALING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MALAISE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUCOSAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
OEDEMA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
OEDEMA PERIPHERAL			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

<p>PYREXIA</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>SWELLING</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>SWELLING FACE</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>TENDERNESS</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>FACIAL PAIN</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>			
	0 / 3 (0.00%)	2 / 4 (50.00%)	2 / 6 (33.33%)
	0	2	2
	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
	0	0	0
	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
	0	0	0
	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
	0	0	0
	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
	0	0	0
<p>Reproductive system and breast disorders</p> <p>BREAST ATROPHY</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>BREAST PAIN</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ENDOMETRIAL THICKENING</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>OEDEMA GENITAL</p> <p>alternative assessment type:</p>			
	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
	0	0	0
	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
	0	0	1
	1 / 3 (33.33%)	0 / 4 (0.00%)	2 / 6 (33.33%)
	1	0	2

Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PELVIC PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
UTERINE POLYP			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
VAGINAL DISCHARGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VAGINAL HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
VULVOVAGINAL DRYNESS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DYSpareunia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
ASTHMA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
COUGH			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	2 / 6 (33.33%)
occurrences (all)	1	1	2
DRY THROAT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DYSпноEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
DYSпноEA EXERTIONAL			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HAEMOPTYSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NASAL CONGESTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
OROPHARYNGEAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
PRODUCTIVE COUGH			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
PULMONARY EMBOLISM			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

RHINORRHOEA alternative assessment type: Systematic	subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
UPPER-AIRWAY COUGH SYNDROME alternative assessment type: Systematic	subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
WHEEZING alternative assessment type: Systematic	subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
EPISTAXIS alternative assessment type: Systematic	subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
HYPOXIA alternative assessment type: Systematic	subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
	occurrences (all)	0	0	1
PLEURAL EFFUSION alternative assessment type: Systematic	subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	1	0	0
Psychiatric disorders				
	ANXIETY alternative assessment type: Systematic			
	subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	1	0	0
	DEPRESSION alternative assessment type: Systematic			
	subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
	INSOMNIA alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MOOD SWINGS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SUICIDAL IDEATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
IRRITABILITY			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
MOOD ALTERED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 3 (66.67%)	1 / 4 (25.00%)	3 / 6 (50.00%)
occurrences (all)	2	1	4
ASPARTATE AMINOTRANSFERASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 3 (66.67%)	1 / 4 (25.00%)	4 / 6 (66.67%)
occurrences (all)	2	1	7
BLOOD ALKALINE PHOSPHATASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	2 / 6 (33.33%)
occurrences (all)	0	1	2
BLOOD BILIRUBIN INCREASED			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLOOD CREATININE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLOOD LACTATE DEHYDROGENASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	3 / 6 (50.00%)
occurrences (all)	0	0	4
BLOOD PHOSPHORUS INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLOOD URIC ACID INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HAEMOGLOBIN DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
LIVER FUNCTION TEST INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NEUTROPHIL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
TRANSAMINASES INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

WEIGHT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
WEIGHT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
WHITE BLOOD CELL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	1 / 6 (16.67%)
occurrences (all)	1	1	1
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
AMYLASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
BILIRUBIN CONJUGATED INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLOOD ALKALINE PHOSPHATASE DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
BLOOD CHLORIDE DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

BLOOD CHOLESTEROL INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	4 / 6 (66.67%)
occurrences (all)	1	0	6
BLOOD THYROID STIMULATING HORMONE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLOOD URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CRYSTAL URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
GLUCOSE URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HIGH DENSITY LIPOPROTEIN DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HIGH DENSITY LIPOPROTEIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
LOW DENSITY LIPOPROTEIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	3 / 6 (50.00%)
occurrences (all)	0	0	5
LYMPHOCYTE COUNT DECREASED			

alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
NEUTROPHIL COUNT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NITRITE URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PLATELET COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RED BLOOD CELL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
RED BLOOD CELLS URINE POSITIVE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
URINARY CASTS PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
WHITE BLOOD CELL COUNT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			

CONTUSION				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	0	1	
FALL				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
HAND FRACTURE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
PELVIC FRACTURE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
PROCEDURAL PAIN				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	0	1	
ARTHROPOD BITE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	0	1	
MUSCLE STRAIN				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	1	0	0	
RIB FRACTURE				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	2	0	0	
SKIN LACERATION				
alternative assessment type: Systematic				

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
SPINAL FRACTURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
WOUND			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Cardiac disorders			
ANGINA PECTORIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BRADYCARDIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PALPITATIONS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
SINUS TACHYCARDIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PERICARDIAL EFFUSION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
SINUS BRADYCARDIA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
ATAXIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DIZZINESS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
DYSGEUSIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HEADACHE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
HYPERSONMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MEMORY IMPAIRMENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MIGRAINE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NEUROPATHY PERIPHERAL			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
PARAESTHESIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PERIPHERAL SENSORY NEUROPATHY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SCIATICA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
TASTE DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VOCAL CORD PARALYSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LETHARGY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
ANAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	2 / 4 (50.00%)	1 / 6 (16.67%)
occurrences (all)	1	2	2
LYMPHOPENIA			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
NEUTROPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
THROMBOCYTOPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
EAR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
EXTERNAL EAR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
TINNITUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
BLEPHARITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DRY EYE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
EYELID PTOSIS			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VISION BLURRED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
IDIOPATHIC ORBITAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LACRIMATION INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
PHOTOPSIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
ABDOMINAL DISCOMFORT			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
ABDOMINAL DISTENSION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	2	0	1
ABDOMINAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 3 (66.67%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	2	0	1
ABDOMINAL PAIN LOWER			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
ABDOMINAL PAIN UPPER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
COLITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CONSTIPATION			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 3 (66.67%)	0 / 4 (0.00%)	2 / 6 (33.33%)
occurrences (all)	2	0	2
DIARRHOEA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	4 / 6 (66.67%)
occurrences (all)	1	2	12
DRY MOUTH			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	3 / 6 (50.00%)
occurrences (all)	0	0	3
DYSPEPSIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
DYSPHAGIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
ERUCTATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

FLATULENCE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	5 / 6 (83.33%)
occurrences (all)	0	0	6
GASTROINTESTINAL HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GASTROOESOPHAGEAL REFLUX DISEASE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	5 / 6 (83.33%)
occurrences (all)	0	0	5
HAEMORRHOIDAL HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HAEMORRHOIDS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
NAUSEA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	3 / 4 (75.00%)	4 / 6 (66.67%)
occurrences (all)	1	4	4
PANCREATITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
STOMATITIS			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 3 (66.67%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	2	0	2
VOMITING			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 3 (33.33%)	2 / 4 (50.00%)	1 / 6 (16.67%)
occurrences (all)	1	3	3
ASCITES			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
FAECES SOFT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
GASTROINTESTINAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
GINGIVAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GINGIVAL SWELLING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LIP SWELLING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ORAL MUCOSAL ERUPTION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
SMALL INTESTINAL OBSTRUCTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Skin and subcutaneous tissue disorders			
ACNE			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
ALOPECIA			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
BLISTER			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DERMATITIS ACNEIFORM			
alternative assessment type:			
Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
DRY SKIN			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
ERYTHEMA			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HYPERHIDROSIS			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PAPULE			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PRURITUS			
alternative assessment type:			
Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
RASH			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
RASH MACULO-PAPULAR			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
SKIN ULCER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
URTICARIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
ERYTHEMA MULTIFORME			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LICHEN SCLEROSUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MACULE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
MADAROSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

PAIN OF SKIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	1 / 6 (16.67%) 1
RASH ERYTHEMATOUS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0
Renal and urinary disorders ACUTE KIDNEY INJURY alternative assessment type: Systematic subjects affected / exposed occurrences (all) DYSURIA alternative assessment type: Systematic subjects affected / exposed occurrences (all) HAEMATURIA alternative assessment type: Systematic subjects affected / exposed occurrences (all) MICTURITION URGENCY alternative assessment type: Systematic subjects affected / exposed occurrences (all) URINARY RETENTION alternative assessment type: Systematic subjects affected / exposed occurrences (all) URINARY TRACT PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all) PROTEINURIA alternative assessment type: Systematic	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
RENAL DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
URINARY TRACT DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	3 / 6 (50.00%)
occurrences (all)	1	0	3
BACK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	3 / 6 (50.00%)
occurrences (all)	0	1	4
BONE PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
FLANK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUSCLE SPASMS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	2 / 4 (50.00%)	2 / 6 (33.33%)
occurrences (all)	1	2	4
MUSCULAR WEAKNESS			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
MUSCULOSKELETAL CHEST PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
MUSCULOSKELETAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL STIFFNESS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MYALGIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
NECK MASS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NECK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	3
OSTEONECROSIS OF JAW			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PAIN IN EXTREMITY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

PAIN IN JAW alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0
SPINAL PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0
GROIN PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0
JOINT STIFFNESS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0
Infections and infestations CELLULITIS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0
DIVERTICULITIS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0
EYE INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0
HERPES ZOSTER alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0
INFECTION alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LOCALISED INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NASOPHARYNGITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ORAL HERPES			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PNEUMONIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
SINUSITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SKIN INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
STAPHYLOCOCCAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
TOOTH INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

UPPER RESPIRATORY TRACT INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
URINARY TRACT INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
VAGINAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VIRAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL MYCOTIC INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BREAST CELLULITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BRONCHITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CROUP INFECTIOUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FUNGAL INFECTION			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
FURUNCLE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
GASTROENTERITIS NOROVIRUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS VIRAL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
GINGIVITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HELICOBACTER INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INFLUENZA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ORAL CANDIDIASIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
OTITIS EXTERNA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

VIRAL UPPER RESPIRATORY TRACT INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1	0 / 6 (0.00%) 0
WOUND INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0
Metabolism and nutrition disorders DECREASED APPETITE alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1	1 / 6 (16.67%) 1
DEHYDRATION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0
HYPERGLYCAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1	2 / 6 (33.33%) 3
HYPERKALAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 4 (25.00%) 1	1 / 6 (16.67%) 1
HYPERTRIGLYCERIDAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 3 (66.67%) 3	1 / 4 (25.00%) 1	3 / 6 (50.00%) 5
HYPERURICAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 4 (0.00%) 0	2 / 6 (33.33%) 6
HYPOALBUMINAEMIA alternative assessment type:			

Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOCALCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
HYPOGLYCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
HYPOMAGNESAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPONATRAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HYPOPHOSPHATAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
HYPERCALCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
HYPERMAGNESAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	3	1	0
HYPERPROTEINAEMIA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOCHLORAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOKALAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Phase Ia – Cohort 3	Phase Ia – Cohort 9	Phase Ia – Cohort 5
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 4 (100.00%)	3 / 3 (100.00%)	6 / 6 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
METASTASIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SQUAMOUS CELL CARCINOMA OF SKIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
DEEP VEIN THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FLUSHING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HAEMATOMA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HOT FLUSH			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HYPERTENSION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	5
PALLOR			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LYMPHOEDEMA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
ASTHENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CHEST DISCOMFORT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CHEST PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
CHILLS			
alternative assessment type: Systematic			

subjects affected / exposed	3 / 4 (75.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
FATIGUE			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 4 (75.00%)	3 / 3 (100.00%)	5 / 6 (83.33%)
occurrences (all)	3	7	6
GAIT DISTURBANCE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
IMPAIRED HEALING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MALAISE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUCOSAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
OEDEMA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
OEDEMA PERIPHERAL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	3 / 6 (50.00%)
occurrences (all)	0	0	3
PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

PYREXIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
SWELLING alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
SWELLING FACE alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
TENDERNESS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
FACIAL PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Reproductive system and breast disorders BREAST ATROPHY alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
BREAST PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
ENDOMETRIAL THICKENING alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
OEDEMA GENITAL alternative assessment type:			

Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PELVIC PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
UTERINE POLYP			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VAGINAL DISCHARGE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences (all)	1	2	1
VAGINAL HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL DRYNESS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DYSpareunia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
ASTHMA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
COUGH			
alternative assessment type: Systematic			

subjects affected / exposed	2 / 4 (50.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	3	0	1
DRY THROAT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DYSпноEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DYSпноEA EXERTIONAL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HAEMOPTYSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NASAL CONGESTION			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 4 (50.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
OROPHARYNGEAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PRODUCTIVE COUGH			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PULMONARY EMBOLISM			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

RHINORRHOEA alternative assessment type: Systematic	subjects affected / exposed	2 / 4 (50.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	2	0	0
UPPER-AIRWAY COUGH SYNDROME alternative assessment type: Systematic	subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
WHEEZING alternative assessment type: Systematic	subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
EPISTAXIS alternative assessment type: Systematic	subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
	occurrences (all)	0	0	1
HYPOXIA alternative assessment type: Systematic	subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
PLEURAL EFFUSION alternative assessment type: Systematic	subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
Psychiatric disorders	ANXIETY alternative assessment type: Systematic			
	subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
	occurrences (all)	0	0	1
	DEPRESSION alternative assessment type: Systematic			
	subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
	occurrences (all)	0	2	0
	INSOMNIA alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MOOD SWINGS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SUICIDAL IDEATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
IRRITABILITY			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
MOOD ALTERED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	2 / 3 (66.67%)	3 / 6 (50.00%)
occurrences (all)	0	3	5
ASPARTATE AMINOTRANSFERASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	2 / 3 (66.67%)	3 / 6 (50.00%)
occurrences (all)	0	3	4
BLOOD ALKALINE PHOSPHATASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
BLOOD BILIRUBIN INCREASED			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLOOD CREATININE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLOOD LACTATE DEHYDROGENASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
BLOOD PHOSPHORUS INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLOOD URIC ACID INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HAEMOGLOBIN DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LIVER FUNCTION TEST INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NEUTROPHIL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
TRANSAMINASES INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

WEIGHT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	4
WEIGHT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
WHITE BLOOD CELL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 4 (50.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	3	0	3
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
AMYLASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BILIRUBIN CONJUGATED INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLOOD ALKALINE PHOSPHATASE DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLOOD CHLORIDE DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

BLOOD CHOLESTEROL INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
BLOOD THYROID STIMULATING HORMONE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLOOD URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
CRYSTAL URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GLUCOSE URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HIGH DENSITY LIPOPROTEIN DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HIGH DENSITY LIPOPROTEIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LOW DENSITY LIPOPROTEIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
LYMPHOCYTE COUNT DECREASED			

alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0
NEUTROPHIL COUNT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NITRITE URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PLATELET COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
RED BLOOD CELL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
RED BLOOD CELLS URINE POSITIVE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
URINARY CASTS PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
WHITE BLOOD CELL COUNT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			

CONTUSION				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
FALL				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
HAND FRACTURE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
PELVIC FRACTURE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
PROCEDURAL PAIN				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
ARTHROPOD BITE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
MUSCLE STRAIN				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
RIB FRACTURE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
SKIN LACERATION				
alternative assessment type: Systematic				

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SPINAL FRACTURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
WOUND			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
ANGINA PECTORIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BRADYCARDIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PALPITATIONS			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 4 (50.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0
SINUS TACHYCARDIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
PERICARDIAL EFFUSION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SINUS BRADYCARDIA			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
ATAXIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
DIZZINESS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences (all)	1	1	1
DYSGEUSIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
HEADACHE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
HYPERSONMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MEMORY IMPAIRMENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MIGRAINE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NEUROPATHY PERIPHERAL			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PARAESTHESIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PERIPHERAL SENSORY NEUROPATHY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SCIATICA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
TASTE DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
VOCAL CORD PARALYSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LETHARGY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
ANAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 4 (50.00%)	2 / 3 (66.67%)	4 / 6 (66.67%)
occurrences (all)	3	3	13
LYMPHOPENIA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
NEUTROPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
THROMBOCYTOPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Ear and labyrinth disorders			
EAR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
EXTERNAL EAR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
TINNITUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
BLEPHARITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DRY EYE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
EYELID PTOSIS			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VISION BLURRED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
IDIOPATHIC ORBITAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LACRIMATION INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PHOTOPSIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
ABDOMINAL DISCOMFORT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL DISTENSION			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 4 (50.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
ABDOMINAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 4 (75.00%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences (all)	3	1	1
ABDOMINAL PAIN LOWER			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN UPPER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
COLITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CONSTIPATION			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 4 (75.00%)	2 / 3 (66.67%)	2 / 6 (33.33%)
occurrences (all)	3	2	2
DIARRHOEA			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 4 (100.00%)	3 / 3 (100.00%)	6 / 6 (100.00%)
occurrences (all)	11	6	22
DRY MOUTH			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
DYSPEPSIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	1 / 3 (33.33%)	2 / 6 (33.33%)
occurrences (all)	1	1	2
DYSPHAGIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ERUCTATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

FLATULENCE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)	
occurrences (all)	0	0	2	
GASTROINTESTINAL HAEMORRHAGE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
GASTROOESOPHAGEAL REFLUX DISEASE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)	
occurrences (all)	0	2	0	
HAEMORRHOIDAL HAEMORRHAGE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	0	1	
HAEMORRHOIDS				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
NAUSEA				
alternative assessment type: Systematic				
subjects affected / exposed	2 / 4 (50.00%)	2 / 3 (66.67%)	2 / 6 (33.33%)	
occurrences (all)	4	7	3	
PANCREATITIS				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
STOMATITIS				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 4 (25.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)	
occurrences (all)	1	1	0	
VOMITING				
alternative assessment type: Systematic				

subjects affected / exposed	1 / 4 (25.00%)	2 / 3 (66.67%)	1 / 6 (16.67%)
occurrences (all)	1	4	3
ASCITES			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FAECES SOFT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GASTROINTESTINAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GINGIVAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
GINGIVAL SWELLING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LIP SWELLING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
ORAL MUCOSAL ERUPTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SMALL INTESTINAL OBSTRUCTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

Skin and subcutaneous tissue disorders			
ACNE			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ALOPECIA			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLISTER			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DERMATITIS ACNEIFORM			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DRY SKIN			
alternative assessment type:			
Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
ERYTHEMA			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
HYPERHIDROSIS			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PAPULE			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PRURITUS			
alternative assessment type:			
Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RASH			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RASH MACULO-PAPULAR			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
SKIN ULCER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
URTICARIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ERYTHEMA MULTIFORME			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
LICHEN SCLEROSUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
MACULE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MADAROSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

PAIN OF SKIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
RASH ERYTHEMATOUS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Renal and urinary disorders ACUTE KIDNEY INJURY alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
DYSURIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
HAEMATURIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
MICTURITION URGENCY alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
URINARY RETENTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
URINARY TRACT PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
PROTEINURIA alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RENAL DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
URINARY TRACT DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	1 / 3 (33.33%)	4 / 6 (66.67%)
occurrences (all)	1	3	5
BACK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 4 (50.00%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences (all)	2	1	1
BONE PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FLANK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUSCLE SPASMS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
MUSCULAR WEAKNESS			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL CHEST PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
MUSCULOSKELETAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL STIFFNESS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MYALGIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
NECK MASS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NECK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
OSTEONECROSIS OF JAW			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PAIN IN EXTREMITY			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	2 / 3 (66.67%)	1 / 6 (16.67%)
occurrences (all)	1	2	2

PAIN IN JAW alternative assessment type: Systematic	subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
SPINAL PAIN alternative assessment type: Systematic	subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
GROIN PAIN alternative assessment type: Systematic	subjects affected / exposed	1 / 4 (25.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
	occurrences (all)	1	1	0
JOINT STIFFNESS alternative assessment type: Systematic	subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	1	0	0
Infections and infestations	CELLULITIS alternative assessment type: Systematic			
	subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
	occurrences (all)	0	0	1
	DIVERTICULITIS alternative assessment type: Systematic			
	subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	1	0	0
	EYE INFECTION alternative assessment type: Systematic			
	subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
	occurrences (all)	0	0	1
	HERPES ZOSTER alternative assessment type: Systematic			
	subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
	INFECTION alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LOCALISED INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NASOPHARYNGITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ORAL HERPES			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PNEUMONIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
SINUSITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SKIN INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
STAPHYLOCOCCAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
TOOTH INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

UPPER RESPIRATORY TRACT INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	1	0	3
URINARY TRACT INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VAGINAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VIRAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL MYCOTIC INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BREAST CELLULITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BRONCHITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CROUP INFECTIOUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FUNGAL INFECTION			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FURUNCLE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS NOROVIRUS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
GASTROENTERITIS VIRAL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GINGIVITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HELICOBACTER INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
INFLUENZA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
ORAL CANDIDIASIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
OTITIS EXTERNA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

VIRAL UPPER RESPIRATORY TRACT INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
WOUND INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Metabolism and nutrition disorders DECREASED APPETITE alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	2 / 3 (66.67%) 6	2 / 6 (33.33%) 2
DEHYDRATION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 2	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
HYPERGLYCAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	1 / 3 (33.33%) 2	2 / 6 (33.33%) 3
HYPERKALAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 3 (33.33%) 2	0 / 6 (0.00%) 0
HYPERTRIGLYCERIDAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	2 / 3 (66.67%) 2	1 / 6 (16.67%) 1
HYPERURICAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
HYPOALBUMINAEMIA alternative assessment type:			

Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOCALCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HYPOGLYCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOMAGNESAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences (all)	0	1	3
HYPONATRAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	1	0	3
HYPOPHOSPHATAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	3 / 6 (50.00%)
occurrences (all)	0	0	3
HYPERCALCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HYPERMAGNESAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPERPROTEINAEMIA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOCHLORAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HYPOKALAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Phase Ia – Cohort 4	Phase Ia – Cohort 8	Phase Ia – Cohort 7
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6 / 6 (100.00%)	3 / 3 (100.00%)	6 / 6 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
METASTASIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SQUAMOUS CELL CARCINOMA OF SKIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
DEEP VEIN THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FLUSHING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HAEMATOMA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HOT FLUSH			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	2	0	2
HYPERTENSION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
PALLOR			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LYMPHOEDEMA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
ASTHENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CHEST DISCOMFORT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
CHEST PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CHILLS			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
FATIGUE			
alternative assessment type: Systematic			
subjects affected / exposed	5 / 6 (83.33%)	2 / 3 (66.67%)	6 / 6 (100.00%)
occurrences (all)	7	3	12
GAIT DISTURBANCE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
IMPAIRED HEALING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MALAISE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUCOSAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
OEDEMA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
OEDEMA PERIPHERAL			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

<p>PYREXIA</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>SWELLING</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>SWELLING FACE</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>TENDERNESS</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>FACIAL PAIN</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>			
	0 / 6 (0.00%)	1 / 3 (33.33%)	2 / 6 (33.33%)
	0	1	2
	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	0	0	0
	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
	0	1	0
	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	0	0	0
	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
	0	1	0
<p>Reproductive system and breast disorders</p> <p>BREAST ATROPHY</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>BREAST PAIN</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ENDOMETRIAL THICKENING</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>OEDEMA GENITAL</p> <p>alternative assessment type:</p>			
	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	0	0	0
	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	0	0	0
	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	0	0	0

Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PELVIC PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
UTERINE POLYP			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
VAGINAL DISCHARGE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
VAGINAL HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL DRYNESS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
DYSpareunia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
ASTHMA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
COUGH			
alternative assessment type: Systematic			

subjects affected / exposed	2 / 6 (33.33%)	2 / 3 (66.67%)	2 / 6 (33.33%)
occurrences (all)	2	2	2
DRY THROAT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DYSпноEA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	1 / 3 (33.33%)	2 / 6 (33.33%)
occurrences (all)	1	1	2
DYSпноEA EXERTIONAL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HAEMOPTYSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NASAL CONGESTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
OROPHARYNGEAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PRODUCTIVE COUGH			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
PULMONARY EMBOLISM			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

RHINORRHOEA alternative assessment type: Systematic	subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
UPPER-AIRWAY COUGH SYNDROME alternative assessment type: Systematic	subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	1	0	0
WHEEZING alternative assessment type: Systematic	subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
EPISTAXIS alternative assessment type: Systematic	subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
HYPOXIA alternative assessment type: Systematic	subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
PLEURAL EFFUSION alternative assessment type: Systematic	subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	0	0	0
Psychiatric disorders	ANXIETY alternative assessment type: Systematic			
	subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
	occurrences (all)	1	0	0
	DEPRESSION alternative assessment type: Systematic			
	subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
	occurrences (all)	0	0	1
	INSOMNIA alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MOOD SWINGS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SUICIDAL IDEATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
IRRITABILITY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
MOOD ALTERED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 6 (50.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	8	0	0
ASPARTATE AMINOTRANSFERASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 6 (66.67%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	6	0	1
BLOOD ALKALINE PHOSPHATASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 6 (50.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	4	0	2
BLOOD BILIRUBIN INCREASED			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
BLOOD CREATININE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
BLOOD LACTATE DEHYDROGENASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
BLOOD PHOSPHORUS INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
BLOOD URIC ACID INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HAEMOGLOBIN DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LIVER FUNCTION TEST INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NEUTROPHIL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	5	0	0
TRANSAMINASES INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

WEIGHT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
WEIGHT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
WHITE BLOOD CELL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	10	1	0
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
AMYLASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BILIRUBIN CONJUGATED INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
BLOOD ALKALINE PHOSPHATASE DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLOOD CHLORIDE DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

BLOOD CHOLESTEROL INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
BLOOD THYROID STIMULATING HORMONE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
BLOOD URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CRYSTAL URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
GLUCOSE URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HIGH DENSITY LIPOPROTEIN DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HIGH DENSITY LIPOPROTEIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
LOW DENSITY LIPOPROTEIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
LYMPHOCYTE COUNT DECREASED			

alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
NEUTROPHIL COUNT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
NITRITE URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
PLATELET COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RED BLOOD CELL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
RED BLOOD CELLS URINE POSITIVE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
URINARY CASTS PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
WHITE BLOOD CELL COUNT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications			

CONTUSION				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
FALL				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
HAND FRACTURE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)	
occurrences (all)	0	1	0	
PELVIC FRACTURE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
PROCEDURAL PAIN				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
ARTHROPOD BITE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
MUSCLE STRAIN				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
RIB FRACTURE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)	
occurrences (all)	0	0	0	
SKIN LACERATION				
alternative assessment type: Systematic				

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SPINAL FRACTURE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
WOUND			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
ANGINA PECTORIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BRADYCARDIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PALPITATIONS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SINUS TACHYCARDIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
PERICARDIAL EFFUSION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SINUS BRADYCARDIA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
ATAXIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DIZZINESS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
DYSGEUSIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
HEADACHE			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
HYPERSONMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MEMORY IMPAIRMENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MIGRAINE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NEUROPATHY PERIPHERAL			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
PARAESTHESIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PERIPHERAL SENSORY NEUROPATHY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SCIATICA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
TASTE DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	2 / 6 (33.33%)
occurrences (all)	0	1	2
VOCAL CORD PARALYSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LETHARGY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Blood and lymphatic system disorders			
ANAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 6 (50.00%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences (all)	3	1	3
LYMPHOPENIA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	3
NEUTROPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
THROMBOCYTOPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
EAR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
EXTERNAL EAR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
TINNITUS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Eye disorders			
BLEPHARITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DRY EYE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
EYELID PTOSIS			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VISION BLURRED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
IDIOPATHIC ORBITAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
LACRIMATION INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PHOTOPSIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
ABDOMINAL DISCOMFORT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
ABDOMINAL DISTENSION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	2	0	1
ABDOMINAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	3	0	1
ABDOMINAL PAIN LOWER			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL PAIN UPPER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
COLITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CONSTIPATION			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 6 (66.67%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	7	0	5
DIARRHOEA			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 6 (66.67%)	3 / 3 (100.00%)	6 / 6 (100.00%)
occurrences (all)	6	7	21
DRY MOUTH			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	2	0	2
DYSPEPSIA			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	1 / 3 (33.33%)	2 / 6 (33.33%)
occurrences (all)	2	2	2
DYSPHAGIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ERUCTATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

FLATULENCE			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences (all)	3	1	1
GASTROINTESTINAL HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GASTROOESOPHAGEAL REFLUX DISEASE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HAEMORRHOIDAL HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HAEMORRHOIDS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NAUSEA			
alternative assessment type: Systematic			
subjects affected / exposed	6 / 6 (100.00%)	2 / 3 (66.67%)	6 / 6 (100.00%)
occurrences (all)	11	2	15
PANCREATITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
STOMATITIS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
VOMITING			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 6 (16.67%)	3 / 3 (100.00%)	4 / 6 (66.67%)
occurrences (all)	2	5	15
ASCITES			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FAECES SOFT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GASTROINTESTINAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GINGIVAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GINGIVAL SWELLING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
LIP SWELLING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ORAL MUCOSAL ERUPTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SMALL INTESTINAL OBSTRUCTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Skin and subcutaneous tissue disorders			
ACNE			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ALOPECIA			
alternative assessment type:			
Systematic			
subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
BLISTER			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DERMATITIS ACNEIFORM			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
DRY SKIN			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ERYTHEMA			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPERHIDROSIS			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PAPULE			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PRURITUS			
alternative assessment type:			
Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RASH			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RASH MACULO-PAPULAR			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SKIN ULCER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
URTICARIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ERYTHEMA MULTIFORME			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LICHEN SCLEROSUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MACULE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MADAROSIS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

PAIN OF SKIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
RASH ERYTHEMATOUS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Renal and urinary disorders ACUTE KIDNEY INJURY alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
DYSURIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
HAEMATURIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
MICTURITION URGENCY alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
URINARY RETENTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
URINARY TRACT PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
PROTEINURIA alternative assessment type: Systematic			

subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
RENAL DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
URINARY TRACT DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
BACK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
BONE PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FLANK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUSCLE SPASMS			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences (all)	3	1	1
MUSCULAR WEAKNESS			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL CHEST PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
MUSCULOSKELETAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
MUSCULOSKELETAL STIFFNESS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MYALGIA			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	4	0	0
NECK MASS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NECK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0
OSTEONECROSIS OF JAW			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PAIN IN EXTREMITY			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

PAIN IN JAW alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
SPINAL PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
GROIN PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
JOINT STIFFNESS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Infections and infestations CELLULITIS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
DIVERTICULITIS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
EYE INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
HERPES ZOSTER alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
INFECTION alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LOCALISED INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NASOPHARYNGITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
ORAL HERPES			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PNEUMONIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
SINUSITIS			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
SKIN INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
STAPHYLOCOCCAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
TOOTH INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

UPPER RESPIRATORY TRACT INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
URINARY TRACT INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
VAGINAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VIRAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL MYCOTIC INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
BREAST CELLULITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
BRONCHITIS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
CROUP INFECTIOUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
FUNGAL INFECTION			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
FURUNCLE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS NOROVIRUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS VIRAL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GINGIVITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
HELICOBACTER INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INFLUENZA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ORAL CANDIDIASIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
OTITIS EXTERNA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

VIRAL UPPER RESPIRATORY TRACT INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
WOUND INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Metabolism and nutrition disorders DECREASED APPETITE alternative assessment type: Systematic subjects affected / exposed occurrences (all)	3 / 6 (50.00%) 4	0 / 3 (0.00%) 0	2 / 6 (33.33%) 2
DEHYDRATION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
HYPERGLYCAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	2 / 6 (33.33%) 2
HYPERKALAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
HYPERTRIGLYCERIDAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
HYPERURICAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	3 / 6 (50.00%) 4	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
HYPOALBUMINAEMIA alternative assessment type:			

Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HYPOCALCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOGLYCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOMAGNESAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
HYPONATRAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 6 (33.33%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences (all)	4	1	1
HYPOPHOSPHATAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HYPERCALCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HYPERMAGNESAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HYPERPROTEINAEMIA			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HYPOCHLORAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOKALAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	3	0	0

Non-serious adverse events	Phase IIa – Cohort A1	Phase IIa – Cohort A2	Phase IIa – Cohort B2
Total subjects affected by non-serious adverse events			
subjects affected / exposed	18 / 19 (94.74%)	10 / 10 (100.00%)	19 / 19 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
METASTASIS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
SQUAMOUS CELL CARCINOMA OF SKIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
DEEP VEIN THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
FLUSHING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
HAEMATOMA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
HOT FLUSH			
alternative assessment type: Systematic			
subjects affected / exposed	7 / 19 (36.84%)	0 / 10 (0.00%)	9 / 19 (47.37%)
occurrences (all)	7	0	9
HYPERTENSION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
PALLOR			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
LYMPHOEDEMA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
ASTHENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
CHEST DISCOMFORT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
CHEST PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
CHILLS			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 19 (5.26%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
FATIGUE			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 19 (42.11%)	2 / 10 (20.00%)	7 / 19 (36.84%)
occurrences (all)	9	3	7
GAIT DISTURBANCE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
IMPAIRED HEALING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
MALAISE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
MUCOSAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
OEDEMA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
OEDEMA PERIPHERAL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0

<p>PYREXIA</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>SWELLING</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>SWELLING FACE</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>TENDERNESS</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>FACIAL PAIN</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>			
	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
	0	0	1
	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
	0	1	0
	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
	0	0	1
	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	1	0	0
	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	0	0	0
<p>Reproductive system and breast disorders</p> <p>BREAST ATROPHY</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>BREAST PAIN</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ENDOMETRIAL THICKENING</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>OEDEMA GENITAL</p> <p>alternative assessment type:</p>			
	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	0	0	0
	0 / 19 (0.00%)	1 / 10 (10.00%)	1 / 19 (5.26%)
	0	1	1
	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	0	0	0

Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
PELVIC PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
UTERINE POLYP			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
VAGINAL DISCHARGE			
alternative assessment type: Systematic			
subjects affected / exposed	9 / 19 (47.37%)	0 / 10 (0.00%)	4 / 19 (21.05%)
occurrences (all)	9	0	4
VAGINAL HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL DRYNESS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
DYSpareunia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
ASTHMA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
COUGH			
alternative assessment type: Systematic			

subjects affected / exposed	2 / 19 (10.53%)	1 / 10 (10.00%)	5 / 19 (26.32%)
occurrences (all)	2	1	6
DRY THROAT			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
DYSпноEA			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 19 (15.79%)	2 / 10 (20.00%)	2 / 19 (10.53%)
occurrences (all)	3	2	2
DYSпноEA EXERTIONAL			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
HAEMOPTYSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
NASAL CONGESTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
OROPHARYNGEAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
PRODUCTIVE COUGH			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
PULMONARY EMBOLISM			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0

RHINORRHOEA alternative assessment type: Systematic	subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
UPPER-AIRWAY COUGH SYNDROME alternative assessment type: Systematic	subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	1	0	0
WHEEZING alternative assessment type: Systematic	subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	1 / 19 (5.26%)
	occurrences (all)	1	0	1
EPISTAXIS alternative assessment type: Systematic	subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
HYPOXIA alternative assessment type: Systematic	subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
PLEURAL EFFUSION alternative assessment type: Systematic	subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
Psychiatric disorders	ANXIETY alternative assessment type: Systematic			
	subjects affected / exposed	1 / 19 (5.26%)	1 / 10 (10.00%)	0 / 19 (0.00%)
	occurrences (all)	1	1	0
	DEPRESSION alternative assessment type: Systematic			
	subjects affected / exposed	1 / 19 (5.26%)	2 / 10 (20.00%)	0 / 19 (0.00%)
	occurrences (all)	1	2	0
	INSOMNIA alternative assessment type: Systematic			

subjects affected / exposed	2 / 19 (10.53%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	2	0	1
MOOD SWINGS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
SUICIDAL IDEATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
IRRITABILITY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
MOOD ALTERED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	2 / 10 (20.00%)	0 / 19 (0.00%)
occurrences (all)	1	2	0
ASPARTATE AMINOTRANSFERASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	2 / 10 (20.00%)	1 / 19 (5.26%)
occurrences (all)	1	2	1
BLOOD ALKALINE PHOSPHATASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
BLOOD BILIRUBIN INCREASED			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
BLOOD CREATININE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
BLOOD LACTATE DEHYDROGENASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
BLOOD PHOSPHORUS INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
BLOOD URIC ACID INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
HAEMOGLOBIN DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
LIVER FUNCTION TEST INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
NEUTROPHIL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
TRANSAMINASES INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

WEIGHT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
WEIGHT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
WHITE BLOOD CELL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
AMYLASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
BILIRUBIN CONJUGATED INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
BLOOD ALKALINE PHOSPHATASE DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
BLOOD CHLORIDE DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

BLOOD CHOLESTEROL INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
BLOOD THYROID STIMULATING HORMONE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
BLOOD URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
CRYSTAL URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
GLUCOSE URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
HIGH DENSITY LIPOPROTEIN DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
HIGH DENSITY LIPOPROTEIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
LOW DENSITY LIPOPROTEIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
LYMPHOCYTE COUNT DECREASED			

alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
NEUTROPHIL COUNT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
NITRITE URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
PLATELET COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
RED BLOOD CELL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
RED BLOOD CELLS URINE POSITIVE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
URINARY CASTS PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
WHITE BLOOD CELL COUNT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			

CONTUSION				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)	
occurrences (all)	0	2	0	
FALL				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)	
occurrences (all)	1	0	0	
HAND FRACTURE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)	
occurrences (all)	0	0	0	
PELVIC FRACTURE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)	
occurrences (all)	0	0	0	
PROCEDURAL PAIN				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)	
occurrences (all)	0	0	0	
ARTHROPOD BITE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)	
occurrences (all)	0	0	0	
MUSCLE STRAIN				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)	
occurrences (all)	0	0	0	
RIB FRACTURE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)	
occurrences (all)	0	0	0	
SKIN LACERATION				
alternative assessment type: Systematic				

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
SPINAL FRACTURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
WOUND			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
ANGINA PECTORIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
BRADYCARDIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
PALPITATIONS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
SINUS TACHYCARDIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
PERICARDIAL EFFUSION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
SINUS BRADYCARDIA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
ATAXIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
DIZZINESS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	1 / 10 (10.00%)	2 / 19 (10.53%)
occurrences (all)	1	2	2
DYSGEUSIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
HEADACHE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
HYPERSONMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
MEMORY IMPAIRMENT			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
MIGRAINE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
NEUROPATHY PERIPHERAL			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
PARAESTHESIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
PERIPHERAL SENSORY NEUROPATHY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
SCIATICA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
TASTE DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
VOCAL CORD PARALYSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
LETHARGY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
ANAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 19 (10.53%)	2 / 10 (20.00%)	4 / 19 (21.05%)
occurrences (all)	2	2	8
LYMPHOPENIA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
NEUTROPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
THROMBOCYTOPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	2 / 10 (20.00%)	0 / 19 (0.00%)
occurrences (all)	0	4	0
Ear and labyrinth disorders			
EAR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
EXTERNAL EAR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
TINNITUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
BLEPHARITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
DRY EYE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
EYELID PTOSIS			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
VISION BLURRED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
IDIOPATHIC ORBITAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
LACRIMATION INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
PHOTOPSIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
ABDOMINAL DISCOMFORT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
ABDOMINAL DISTENSION			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 19 (10.53%)	1 / 10 (10.00%)	1 / 19 (5.26%)
occurrences (all)	2	1	1
ABDOMINAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 19 (15.79%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	3	0	3
ABDOMINAL PAIN LOWER			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
ABDOMINAL PAIN UPPER			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 19 (10.53%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	2	1	0
COLITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
CONSTIPATION			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 19 (10.53%)	0 / 10 (0.00%)	4 / 19 (21.05%)
occurrences (all)	2	0	4
DIARRHOEA			
alternative assessment type: Systematic			
subjects affected / exposed	10 / 19 (52.63%)	5 / 10 (50.00%)	11 / 19 (57.89%)
occurrences (all)	16	11	30
DRY MOUTH			
alternative assessment type: Systematic			
subjects affected / exposed	5 / 19 (26.32%)	0 / 10 (0.00%)	2 / 19 (10.53%)
occurrences (all)	5	0	2
DYSPEPSIA			
alternative assessment type: Systematic			
subjects affected / exposed	6 / 19 (31.58%)	2 / 10 (20.00%)	2 / 19 (10.53%)
occurrences (all)	6	2	2
DYSPHAGIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
ERUCTATION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0

FLATULENCE			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 19 (21.05%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	4	0	0
GASTROINTESTINAL HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
GASTROOESOPHAGEAL REFLUX DISEASE			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 19 (10.53%)	0 / 10 (0.00%)	3 / 19 (15.79%)
occurrences (all)	2	0	5
HAEMORRHOIDAL HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
HAEMORRHOIDS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
NAUSEA			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 19 (42.11%)	6 / 10 (60.00%)	9 / 19 (47.37%)
occurrences (all)	9	6	10
PANCREATITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
STOMATITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
VOMITING			
alternative assessment type: Systematic			

subjects affected / exposed	7 / 19 (36.84%)	4 / 10 (40.00%)	2 / 19 (10.53%)
occurrences (all)	11	5	2
ASCITES			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
FAECES SOFT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
GASTROINTESTINAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
GINGIVAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
GINGIVAL SWELLING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
LIP SWELLING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
ORAL MUCOSAL ERUPTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
SMALL INTESTINAL OBSTRUCTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Skin and subcutaneous tissue disorders			
ACNE			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
ALOPECIA			
alternative assessment type:			
Systematic			
subjects affected / exposed	2 / 19 (10.53%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	2	1	0
BLISTER			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
DERMATITIS ACNEIFORM			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
DRY SKIN			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
ERYTHEMA			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
HYPERHIDROSIS			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
PAPULE			
alternative assessment type:			
Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
PRURITUS			
alternative assessment type:			
Systematic			

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
RASH			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	2 / 10 (20.00%)	2 / 19 (10.53%)
occurrences (all)	0	2	2
RASH MACULO-PAPULAR			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
SKIN ULCER			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
URTICARIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
ERYTHEMA MULTIFORME			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
LICHEN SCLEROSUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
MACULE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
MADAROSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

PAIN OF SKIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0	0 / 10 (0.00%) 0	0 / 19 (0.00%) 0
RASH ERYTHEMATOUS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0	0 / 10 (0.00%) 0	0 / 19 (0.00%) 0
Renal and urinary disorders ACUTE KIDNEY INJURY alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0	0 / 10 (0.00%) 0	1 / 19 (5.26%) 1
DYSURIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0	0 / 10 (0.00%) 0	1 / 19 (5.26%) 1
HAEMATURIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0	0 / 10 (0.00%) 0	0 / 19 (0.00%) 0
MICTURITION URGENCY alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 19 (10.53%) 2	0 / 10 (0.00%) 0	0 / 19 (0.00%) 0
URINARY RETENTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0	1 / 10 (10.00%) 1	0 / 19 (0.00%) 0
URINARY TRACT PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 19 (5.26%) 1	0 / 10 (0.00%) 0	1 / 19 (5.26%) 1
PROTEINURIA alternative assessment type: Systematic			

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
RENAL DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
URINARY TRACT DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 19 (21.05%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	5	0	0
BACK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 19 (21.05%)	0 / 10 (0.00%)	4 / 19 (21.05%)
occurrences (all)	4	0	4
BONE PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
FLANK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
MUSCLE SPASMS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	1 / 10 (10.00%)	1 / 19 (5.26%)
occurrences (all)	1	1	1
MUSCULAR WEAKNESS			
alternative assessment type: Systematic			

subjects affected / exposed	2 / 19 (10.53%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	2	0	0
MUSCULOSKELETAL CHEST PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
MUSCULOSKELETAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
MUSCULOSKELETAL STIFFNESS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
MYALGIA			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 19 (10.53%)	1 / 10 (10.00%)	2 / 19 (10.53%)
occurrences (all)	2	1	2
NECK MASS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
NECK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
OSTEONECROSIS OF JAW			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
PAIN IN EXTREMITY			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 19 (21.05%)	1 / 10 (10.00%)	1 / 19 (5.26%)
occurrences (all)	4	1	1

PAIN IN JAW alternative assessment type: Systematic	subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	1	0	0
SPINAL PAIN alternative assessment type: Systematic	subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	1	0	0
GROIN PAIN alternative assessment type: Systematic	subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
JOINT STIFFNESS alternative assessment type: Systematic	subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
Infections and infestations	CELLULITIS alternative assessment type: Systematic			
	subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
	DIVERTICULITIS alternative assessment type: Systematic			
	subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
	EYE INFECTION alternative assessment type: Systematic			
	subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
	HERPES ZOSTER alternative assessment type: Systematic			
	subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
	occurrences (all)	0	0	1
	INFECTION alternative assessment type: Systematic			

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
LOCALISED INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
NASOPHARYNGITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
ORAL HERPES			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
PNEUMONIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
SINUSITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	3 / 19 (15.79%)
occurrences (all)	0	0	3
SKIN INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
STAPHYLOCOCCAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
TOOTH INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0

UPPER RESPIRATORY TRACT INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
URINARY TRACT INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	2 / 19 (10.53%)
occurrences (all)	0	0	2
VAGINAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	2
VIRAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
VULVOVAGINAL MYCOTIC INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
BREAST CELLULITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
BRONCHITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
CROUP INFECTIOUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
FUNGAL INFECTION			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
FURUNCLE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS NOROVIRUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS VIRAL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
GINGIVITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
HELICOBACTER INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
INFLUENZA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
ORAL CANDIDIASIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
OTITIS EXTERNA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
HYPOCALCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
HYPOGLYCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
HYPOMAGNESAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	2	0
HYPONATRAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
HYPOPHOSPHATAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	2 / 10 (20.00%)	2 / 19 (10.53%)
occurrences (all)	0	3	2
HYPERCALCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
HYPERMAGNESAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
HYPERPROTEINAEMIA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
HYPOCHLORAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
HYPOKALAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Phase IIa – Cohort B1	Phase Ib – Cohort D1	Phase Ib – Cohort C1
Total subjects affected by non-serious adverse events			
subjects affected / exposed	51 / 53 (96.23%)	6 / 6 (100.00%)	4 / 4 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
METASTASIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SQUAMOUS CELL CARCINOMA OF SKIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
DEEP VEIN THROMBOSIS			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 53 (3.77%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	2	0	1
FLUSHING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
HAEMATOMA			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
HOT FLUSH			
alternative assessment type: Systematic			
subjects affected / exposed	10 / 53 (18.87%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	11	0	1
HYPERTENSION			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 53 (3.77%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	2	0	1
PALLOR			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LYMPHOEDEMA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
ASTHENIA			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 53 (7.55%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	4	1	0
CHEST DISCOMFORT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
CHEST PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	2
CHILLS			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 53 (1.89%)	2 / 6 (33.33%)	0 / 4 (0.00%)
occurrences (all)	2	2	0
FATIGUE			
alternative assessment type: Systematic			
subjects affected / exposed	27 / 53 (50.94%)	3 / 6 (50.00%)	2 / 4 (50.00%)
occurrences (all)	29	3	2
GAIT DISTURBANCE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
IMPAIRED HEALING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
MALAISE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
MUCOSAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
OEDEMA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
OEDEMA PERIPHERAL			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 53 (5.66%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 53 (3.77%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0

<p>PYREXIA</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>SWELLING</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>SWELLING FACE</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>TENDERNESS</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>FACIAL PAIN</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>			
	4 / 53 (7.55%)	2 / 6 (33.33%)	0 / 4 (0.00%)
	4	2	0
	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
	1	0	0
	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
	0	0	0
	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
	0	0	0
	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
	0	0	0
<p>Reproductive system and breast disorders</p> <p>BREAST ATROPHY</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>BREAST PAIN</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>ENDOMETRIAL THICKENING</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>OEDEMA GENITAL</p> <p>alternative assessment type:</p>			
	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)
	0	1	0
	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
	0	0	0
	1 / 53 (1.89%)	1 / 6 (16.67%)	0 / 4 (0.00%)
	1	1	0

Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PELVIC PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
UTERINE POLYP			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
VAGINAL DISCHARGE			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 53 (15.09%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	9	1	0
VAGINAL HAEMORRHAGE			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 53 (3.77%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
VULVOVAGINAL DRYNESS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
DYSpareunia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
ASTHMA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
COUGH			
alternative assessment type: Systematic			

subjects affected / exposed	8 / 53 (15.09%)	1 / 6 (16.67%)	1 / 4 (25.00%)
occurrences (all)	11	1	4
DRY THROAT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DYSпноEA			
alternative assessment type: Systematic			
subjects affected / exposed	5 / 53 (9.43%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	5	0	1
DYSпноEA EXERTIONAL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HAEMOPTYSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NASAL CONGESTION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
OROPHARYNGEAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
PRODUCTIVE COUGH			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PULMONARY EMBOLISM			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1

RHINORRHOEA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 53 (3.77%)	0 / 6 (0.00%)	0 / 4 (0.00%)
	2	0	0
UPPER-AIRWAY COUGH SYNDROME alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
	1	0	0
WHEEZING alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
	0	0	1
EPISTAXIS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
	0	0	0
HYPOXIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
	0	0	0
PLEURAL EFFUSION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
	0	0	0
Psychiatric disorders ANXIETY alternative assessment type: Systematic subjects affected / exposed occurrences (all) DEPRESSION alternative assessment type: Systematic subjects affected / exposed occurrences (all) INSOMNIA alternative assessment type: Systematic			
	3 / 53 (5.66%)	0 / 6 (0.00%)	0 / 4 (0.00%)
	3	0	0
	2 / 53 (3.77%)	0 / 6 (0.00%)	0 / 4 (0.00%)
	2	0	0

subjects affected / exposed	5 / 53 (9.43%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	5	1	0
MOOD SWINGS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SUICIDAL IDEATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
IRRITABILITY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MOOD ALTERED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	5 / 53 (9.43%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	6	0	1
ASPARTATE AMINOTRANSFERASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 53 (7.55%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	5	0	1
BLOOD ALKALINE PHOSPHATASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
BLOOD BILIRUBIN INCREASED			
alternative assessment type: Systematic			

subjects affected / exposed	2 / 53 (3.77%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	4	0	0
BLOOD CREATININE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLOOD LACTATE DEHYDROGENASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 53 (3.77%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
BLOOD PHOSPHORUS INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
BLOOD URIC ACID INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
HAEMOGLOBIN DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
LIVER FUNCTION TEST INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NEUTROPHIL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
TRANSAMINASES INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 53 (5.66%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	4	0	0

WEIGHT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 53 (5.66%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
WEIGHT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
WHITE BLOOD CELL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
AMYLASE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BILIRUBIN CONJUGATED INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLOOD ALKALINE PHOSPHATASE DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLOOD CHLORIDE DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

BLOOD CHOLESTEROL INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLOOD THYROID STIMULATING HORMONE INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BLOOD URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CRYSTAL URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GLUCOSE URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HIGH DENSITY LIPOPROTEIN DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HIGH DENSITY LIPOPROTEIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LOW DENSITY LIPOPROTEIN INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LYMPHOCYTE COUNT DECREASED			

alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NEUTROPHIL COUNT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NITRITE URINE PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PLATELET COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RED BLOOD CELL COUNT DECREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RED BLOOD CELLS URINE POSITIVE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
URINARY CASTS PRESENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
WHITE BLOOD CELL COUNT INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			

CONTUSION			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 53 (5.66%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	4	0	0
FALL			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
HAND FRACTURE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
PELVIC FRACTURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
PROCEDURAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 53 (3.77%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
ARTHROPOD BITE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MUSCLE STRAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RIB FRACTURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SKIN LACERATION			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SPINAL FRACTURE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
WOUND			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
ANGINA PECTORIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BRADYCARDIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
PALPITATIONS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SINUS TACHYCARDIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
PERICARDIAL EFFUSION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SINUS BRADYCARDIA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
ATAXIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DIZZINESS			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 53 (3.77%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
DYSGEUSIA			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 53 (7.55%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	4	0	0
HEADACHE			
alternative assessment type: Systematic			
subjects affected / exposed	9 / 53 (16.98%)	2 / 6 (33.33%)	1 / 4 (25.00%)
occurrences (all)	12	3	1
HYPERSONMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
MEMORY IMPAIRMENT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MIGRAINE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NEUROPATHY PERIPHERAL			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
PARAESTHESIA			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 53 (5.66%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	6	1	0
PERIPHERAL SENSORY NEUROPATHY			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 53 (5.66%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	3	0	1
SCIATICA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
TASTE DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VOCAL CORD PARALYSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
LETHARGY			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
ANAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	6 / 53 (11.32%)	0 / 6 (0.00%)	2 / 4 (50.00%)
occurrences (all)	6	0	2
LYMPHOPENIA			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
NEUTROPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	3 / 4 (75.00%)
occurrences (all)	1	0	5
THROMBOCYTOPENIA			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 53 (5.66%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	3	0	1
Ear and labyrinth disorders			
EAR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
EXTERNAL EAR PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
TINNITUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
BLEPHARITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
DRY EYE			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	1 / 6 (16.67%)	1 / 4 (25.00%)
occurrences (all)	1	1	1
EYELID PTOSIS			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VISION BLURRED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
IDIOPATHIC ORBITAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LACRIMATION INCREASED			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PHOTOPSIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
ABDOMINAL DISCOMFORT			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 53 (3.77%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
ABDOMINAL DISTENSION			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 53 (3.77%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
ABDOMINAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	10 / 53 (18.87%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	11	1	0
ABDOMINAL PAIN LOWER			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
ABDOMINAL PAIN UPPER			
alternative assessment type: Systematic			
subjects affected / exposed	6 / 53 (11.32%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	11	0	0
COLITIS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
CONSTIPATION			
alternative assessment type: Systematic			
subjects affected / exposed	16 / 53 (30.19%)	3 / 6 (50.00%)	0 / 4 (0.00%)
occurrences (all)	21	3	0
DIARRHOEA			
alternative assessment type: Systematic			
subjects affected / exposed	28 / 53 (52.83%)	6 / 6 (100.00%)	2 / 4 (50.00%)
occurrences (all)	66	13	2
DRY MOUTH			
alternative assessment type: Systematic			
subjects affected / exposed	6 / 53 (11.32%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	8	0	0
DYSPEPSIA			
alternative assessment type: Systematic			
subjects affected / exposed	6 / 53 (11.32%)	3 / 6 (50.00%)	0 / 4 (0.00%)
occurrences (all)	6	3	0
DYSPHAGIA			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 53 (5.66%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
ERUCTATION			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 53 (3.77%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0

FLATULENCE				
alternative assessment type: Systematic				
subjects affected / exposed	13 / 53 (24.53%)	1 / 6 (16.67%)	0 / 4 (0.00%)	
occurrences (all)	14	1	0	
GASTROINTESTINAL HAEMORRHAGE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	0	
GASTROOESOPHAGEAL REFLUX DISEASE				
alternative assessment type: Systematic				
subjects affected / exposed	9 / 53 (16.98%)	0 / 6 (0.00%)	1 / 4 (25.00%)	
occurrences (all)	10	0	1	
HAEMORRHOIDAL HAEMORRHAGE				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)	
occurrences (all)	0	1	0	
HAEMORRHOIDS				
alternative assessment type: Systematic				
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	0	0	0	
NAUSEA				
alternative assessment type: Systematic				
subjects affected / exposed	24 / 53 (45.28%)	4 / 6 (66.67%)	3 / 4 (75.00%)	
occurrences (all)	32	8	6	
PANCREATITIS				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)	
occurrences (all)	1	0	0	
STOMATITIS				
alternative assessment type: Systematic				
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	1 / 4 (25.00%)	
occurrences (all)	1	0	1	
VOMITING				
alternative assessment type: Systematic				

subjects affected / exposed	14 / 53 (26.42%)	3 / 6 (50.00%)	0 / 4 (0.00%)
occurrences (all)	22	5	0
ASCITES			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
FAECES SOFT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GASTROINTESTINAL INFLAMMATION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GINGIVAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GINGIVAL SWELLING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LIP SWELLING			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ORAL MUCOSAL ERUPTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
SMALL INTESTINAL OBSTRUCTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Skin and subcutaneous tissue disorders			
ACNE			
alternative assessment type:			
Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
ALOPECIA			
alternative assessment type:			
Systematic			
subjects affected / exposed	2 / 53 (3.77%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
BLISTER			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
DERMATITIS ACNEIFORM			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
DRY SKIN			
alternative assessment type:			
Systematic			
subjects affected / exposed	2 / 53 (3.77%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
ERYTHEMA			
alternative assessment type:			
Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
HYPERHIDROSIS			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PAPULE			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PRURITUS			
alternative assessment type:			
Systematic			

subjects affected / exposed	2 / 53 (3.77%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	3	1	0
RASH			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 53 (5.66%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	3	0	1
RASH MACULO-PAPULAR			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
SKIN ULCER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
URTICARIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
ERYTHEMA MULTIFORME			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
LICHEN SCLEROSUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MACULE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
MADAROSIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

PAIN OF SKIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%) 0	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
RASH ERYTHEMATOUS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%) 0	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
Renal and urinary disorders ACUTE KIDNEY INJURY alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%) 0	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
DYSURIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 53 (3.77%) 2	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
HAEMATURIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	4 / 53 (7.55%) 4	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
MICTURITION URGENCY alternative assessment type: Systematic subjects affected / exposed occurrences (all)	4 / 53 (7.55%) 4	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
URINARY RETENTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%) 0	1 / 6 (16.67%) 1	0 / 4 (0.00%) 0
URINARY TRACT PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 53 (1.89%) 1	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
PROTEINURIA alternative assessment type: Systematic			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
RENAL DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
URINARY TRACT DISORDER			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
alternative assessment type: Systematic			
subjects affected / exposed	14 / 53 (26.42%)	1 / 6 (16.67%)	1 / 4 (25.00%)
occurrences (all)	18	2	1
BACK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	13 / 53 (24.53%)	1 / 6 (16.67%)	2 / 4 (50.00%)
occurrences (all)	15	1	2
BONE PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 53 (5.66%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	3	1	0
FLANK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
MUSCLE SPASMS			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 53 (7.55%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	5	0	0
MUSCULAR WEAKNESS			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
MUSCULOSKELETAL CHEST PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	5 / 53 (9.43%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	5	0	2
MUSCULOSKELETAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	7 / 53 (13.21%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	7	0	1
MUSCULOSKELETAL STIFFNESS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
MYALGIA			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 53 (5.66%)	2 / 6 (33.33%)	0 / 4 (0.00%)
occurrences (all)	5	2	0
NECK MASS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
NECK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 53 (5.66%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
OSTEONECROSIS OF JAW			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
PAIN IN EXTREMITY			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 53 (7.55%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	6	0	0

PAIN IN JAW alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%) 0	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
SPINAL PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 53 (1.89%) 1	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
GROIN PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%) 0	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
JOINT STIFFNESS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%) 0	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
Infections and infestations CELLULITIS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 53 (1.89%) 1	0 / 6 (0.00%) 0	1 / 4 (25.00%) 1
DIVERTICULITIS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 53 (1.89%) 1	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
EYE INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 53 (3.77%) 2	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
HERPES ZOSTER alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%) 0	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
INFECTION alternative assessment type: Systematic			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
LOCALISED INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
NASOPHARYNGITIS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
ORAL HERPES			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
PNEUMONIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
SINUSITIS			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 53 (5.66%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
SKIN INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
STAPHYLOCOCCAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
TOOTH INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

UPPER RESPIRATORY TRACT INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	1 / 6 (16.67%)	1 / 4 (25.00%)
occurrences (all)	1	1	1
URINARY TRACT INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 53 (15.09%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	9	0	1
VAGINAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
VIRAL INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL MYCOTIC INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
BREAST CELLULITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
BRONCHITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
CROUP INFECTIOUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
FUNGAL INFECTION			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
FURUNCLE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS NOROVIRUS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GASTROENTERITIS VIRAL			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
GINGIVITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HELICOBACTER INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
INFLUENZA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
ORAL CANDIDIASIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
OTITIS EXTERNA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

VIRAL UPPER RESPIRATORY TRACT INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%) 0	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
WOUND INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 53 (0.00%) 0	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
Metabolism and nutrition disorders DECREASED APPETITE alternative assessment type: Systematic subjects affected / exposed occurrences (all)	9 / 53 (16.98%) 9	4 / 6 (66.67%) 4	1 / 4 (25.00%) 1
DEHYDRATION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 53 (1.89%) 1	1 / 6 (16.67%) 1	0 / 4 (0.00%) 0
HYPERGLYCAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	3 / 53 (5.66%) 4	0 / 6 (0.00%) 0	2 / 4 (50.00%) 2
HYPERKALAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 53 (3.77%) 2	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
HYPERTRIGLYCERIDAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	3 / 53 (5.66%) 3	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
HYPERURICAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 53 (1.89%) 1	0 / 6 (0.00%) 0	0 / 4 (0.00%) 0
HYPOALBUMINAEMIA alternative assessment type:			

Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HYPOCALCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
HYPOGLYCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
HYPOMAGNESAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HYPONATRAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
HYPOPHOSPHATAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 53 (3.77%)	1 / 6 (16.67%)	2 / 4 (50.00%)
occurrences (all)	2	1	2
HYPERCALCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HYPERMAGNESAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HYPERPROTEINAEMIA			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HYPOCHLORAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
HYPOKALAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 April 2013	Protocol was amended with changes to the inclusion/exclusion criteria, clinical laboratory assessments, and PK assessments.
11 October 2013	Protocol was amended to include changes to the sponsor name (Aragon Pharm was changed to Seragon), add exploratory objectives, dose escalation PK and ECG sample collection, and drug access if receiving clinical benefit.
20 June 2014	Protocol was amended to update the inclusion/exclusion criteria, study rationale, name of the dose expansion phase to Phase IIa, dosing regimen, and Phase IIa objectives.
02 January 2015	Protocol was amended to update as the per transfer of IND ownership of GDC-0810 to Genentech Inc.
18 December 2015	Protocol was amended to include Phase Ib combination cohorts with palbociclib and luteinizing hormone releasing hormone (LHRH) agonists
25 January 2017	Protocol was amended to reduce the number of required study procedures as a result of Sponsor decision to halt the development of GDC-0810 and halt enrollment into the study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported